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Fungal infections have a significant impact on the world population, with estimates of
over 1.6 million deaths a year. One contributing factor is the increasing number of fungi resistant
to the current clinical treatments, including the last approved family of antifungal compounds
introduced into the market over a decade ago. This is driving the search for new antifungals with
different biological targets. A new potential antifungal occidiofungin, is a cyclic
glycolipopeptide isolated from the soil bacterium Burkholderia contaminans MS14 with a broad
spectrum of activity against both human and plant pathogens. Kill kinetics demonstrated that this
compound is fungicidal and activates the cell wall integrity pathway at suboptimal dosing as
determined by Mkc1 MAPK phosphorylation studies. As three of the four classes of currently
available antifungals target ergosterol or ergosterol biosynthesis, the bioactivity of occidiofungin
was assayed in the presence of ergosterol containing DOPC vesicles and was shown to retain
antifungal properties. Occidiofungin was also found to have a similar activity profile against the
S. cerevisiae b-1,3-glucan synthesis mutant, indicating that it does not share a target with the
fourth class of antifungals. Stability testing showed occidiofungin retained in vitro potency in the

presence of human serum, across a broad range of pH and temperature conditions, and was
resistant to gastric proteases. Based on cell morphology, occidiofungin did not target a specific
stage of the yeast cell cycle, however cells were smaller in size and acquired ‘dancing bodies’,
both properties of apoptosis. This was confirmed with data showing concentration dependent
increases in DNA fragmentation, reactive oxygen species, and extracellular localization of
phosphatidylserine. In addition to these findings, cells deleted for the yeast caspase gene exhibit
a 2-fold resistance to occidiofungin. While SEM showed no morphological differences between
treated and untreated cells, TEM did identify a thinning of the cell wall and inclusion bodies in
cells treated with occidiofungin. As a stable fungicidal compound that induces apoptosis in yeast,
occidiofungin has a great potential to become a new candidate drug for clinical use in treating
fungal infections, including those resistant to current antifungals.
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CURRENT AND FUTURE ANTIFUNGALS
Candida infections
Candida is a genus of yeast that is part of the normal flora of the human body and skin,
including the intestinal tract and mucous membranes such as in the mouth, throat, and vagina.1
There are over 150 different species of Candida that have been identified, but only about 20 are
known to cause infection.2 Candida albicans and Candida glabrata are the first and second most
clinically prevalent species, respectively. Other clinically relevant species include: C.
parapsilosis, C. tropicalis, and C. krusei. Less common clinical isolates include: C.
dublininensis, C. guilliermondii, C. lusitaniae, C. rugosa, C. orthopsilosis, and C. metapsilosis.3
A new species recently discovered within the last decade, and of clinical relevance, is Candida
auris. This particular species of Candida has been shown to be resistant to multiple currently
available clinical antifungals.4 Although drug resistant species such as this exist, species can
develop or acquire resistance over time.
When the normal flora threshold of Candida is surpassed and there is a fungal
overgrowth, infection can occur, at which point the yeast is considered to be pathogenic.
Depending on the location, different terms are used in diagnosis of the Candida infection. When
in the throat and/or mouth, it is called oropharyngeal candidiasis, or more commonly, ‘thrush’.
Thrush can include multiple symptoms such as: visible growth (colonization of Candida) on the
soft tissues of the oral cavity and throat; redness; loss of taste; difficulty eating or swallowing;
1

and cracking and redness at the corners of the mouth.5 Candidiasis in the esophagus, is known as
esophageal candidiasis or Candida esophagitis.6 Symptoms usually include pain and difficulty
swallowing. Esophageal candidiasis is common for people living with HIV/AIDS.7 While in
healthy adults it is uncommon to have candidiasis of the mouth, throat or esophagus, people at
higher risk for infection include: infants; denture wearers; diabetics; cancer patients; those on
antibiotics; those who take corticosteroids; those who take medications or have medical
conditions resulting in dry mouth; people who smoke, and HIV/AIDS patients.8, 9
When infection occurs in the vagina, it is called vaginal candidiasis, or more commonly
referred to as a ‘vaginal yeast infection’. Other diagnoses include vulvovaginal candidiasis and
Candida vaginitis. Symptoms include: vaginal itching or tenderness; pain during sex; urination
pain; and abnormal vaginal discharge.10 In severe conditions, swelling and cracking of the
vaginal wall can occur. While definitive data is not available to give an exact account on the
number of patients with vaginal candidiasis, next to bacterial infections, it is the second most
prevalent kind of vaginal infection.11 Women who: are pregnant; use hormonal birth control;
have diabetes; have a weakened immune system; or women who are prescribed antibiotics are
more likely to develop vaginal candidiasis.12
Candida infections can also occur in the bloodstream.2 This is a form of invasive
candidiasis called candidemia, and is the most common bloodstream infection in hospitalized
patients in the United States.13, 14 Candidemia can be life threatening to both
immunocompromised individuals as well as healthy patients. At particular risk are patients with
HIV, those undergoing treatment for cancer, or hospitalized patients that acquire a nosocomial
Candida infection. Additionally, individuals with a central venous catheter, are in the intensive
care unit, those prescribed broad-spectrum antibiotics, have low neutrophil counts (neutropenia),
2

have kidney failure or are on hemodialysis, have had surgery, especially gastrointestinal surgery,
or patients who have diabetes are also at risk.15 The most common symptoms of candidemia are
fever and chills that do not improve after antibiotic treatment for misdiagnosed bacterial
infections. If spreading occurs, other symptoms can develop including invasive candidiasis of the
heart, brain, eyes, and bones, as well as other parts of the body.16 Fungal sources for candidemia
include introduction of a patient’s own Candida yeasts during intravenous catheter usage, the
insertion of contaminated medical devices, and even from being carried on healthcare workers’
hands.17, 18
Other types of clinically relevant fungal infections
It has been reported that fungal infections kill over 1.6 million people annually and affect
over one seventh of the planet’s estimated one billion people. These numbers are comparable to
that seen for deaths associated with tuberculosis and more than three-fold greater than that seen
for malaria.19 The most prevalent types of fungal infections affecting the world today, other than
Candida albicans, are infections by Aspergillus spp., Cryptococcus spp., and Pneumocystis
species. Together, these account for more than 90% of deaths reported due to fungal disease.20, 21
Of the 180 species currently known of Aspergillus, less than 40 cause infection. The most
common species known to cause aspergillosis is A. fumigatus.22 Aspergillus is a ubiquitous mold
whose spores are inhaled every day with no negative side effects. However, amongst the
immunocompromised community, these spores account for the majority of all allergic fungal
disease and can cause different types of aspergillosis that vary in symptom severity.23 Allergic
bronchopulmonary aspergillosis causes inflammation, coughing and wheezing, but no infection
and most commonly occurs in patients that already have asthma or cystic fibrosis.24, 25 Allergic
Aspergillus sinusitis causes inflammation and symptoms of infection such as runny nose,
3

stuffiness, and headache, but no infection.26, 27 Aspergilloma, sometimes called a fungus ball, is
literally a ball of Aspergillus that grows in the lungs or sinuses without spreading to the rest of
the body, symptoms include cough, coughing up blood, and shortness of breath, and usually
affect those that already have a lung disease such as tuberculosis, chronic obstructive pulmonary
disease (COPD), or sarcoidosis.25, 28, 29 Chronic pulmonary aspergillosis is unresolved
aspergilloma lasting three months or longer. Additional symptoms include weight loss and
fatigue.25, 28-30 Invasive aspergillosis is a more serious infection that typically affects the
immunocompromised, those that have recently had an organ transplant or a stem cell transplant,
are undergoing chemotherapy, or are being prescribed high doses of corticosteroids, as well as
patients with severe influenza.31, 32 While it primarily affects the lungs, it has the capability of
spreading. Symptoms include fever, chest pain, a cough with or without blood, and shortness of
breath. Cutaneous aspergillosis is typically Aspergillus that enters the body through a cut
introduced in the skin by surgery, burn wounds, intravenous catheter sites, site of traumatic
inoculation or sites with occlusive dressings, however, it can also occur through the spreading of
Aspergillus from somewhere else in the body to the skin.33, 34
Cryptococcus is another ubiquitous fungal pathogen that typically does not affect healthy
people, but rather the immunocompromised community, notably those that have advance
HIV/AIDS, have had an organ transplant, or are taking corticosteroids.35-38 Infections, referred to
as cryptococcosis, are generally caused by either Cryptococcus neoformans or Cryptococcus
gattii that is inhaled from the environment. Lung infections often mimic pneumonia symptoms
including cough, shortness of breath, chest pain, and fever. When an infection spreads from the
lungs to the brain and spinal cord it leads to Cryptococcal meningitis.39 Symptoms include

4

headache, fever, neck pain, nausea and vomiting, sensitivity to light, and confusion or changes in
behavior.37, 40-43
The fungus Pneumocystis jivorecii is responsible for causing Pnemocystis pneumonia
(PCP). It was previously called Pneumocystis carnii and was thought to be a protozoan, but has
since been reclassified as a fungus and renamed.44-46 Like most fungal pathogens it primarily
affects those with weakened immune systems, although an estimated 20% of the healthy
population serves as a carrier for this fungal pathogen.47 PCP is spread from person to person via
being airborne.47-50 Symptoms include fever, cough, difficulty breathing, chest pain, chills and
fatigue.51, 52 AIDS/HIV patients account for about 40% of all PCP infections with the remaining
60% made up of patients that are taking immunosuppressants, have blood cancer, an
autoimmune disease, or have had a stem cell transplant.53 According to a study conducted in
Canada and the United States, PCP was the most common opportunistic infection amongst the
HIV infected population.54 It is also problematic amongst the HIV/AIDS communities of
developing countries.55
Despite the prevalence of pathogenic fungi of human health concern, there are currently
only four main classes of antifungal drugs. These limited four classes include: polyenes,
flucytosine, azoles (which include allylamines), and echinocandins.
Currently available clinical antifungals
Polyenes
The first class of antifungal drugs available to the clinical market were polyenes in the
1950s with the introduction of Amphotericin B deoxycholate (AmpB). Polyenes bind to
ergosterol in the fungal plasma membrane reducing the fluidity of the cell membrane. They are
also considered ‘pore-formers’ as they generate channels in the fungal membrane which leads to
5

the leakage of cellular contents. Polyenes are all products of the Streptomyces species and are
only available in an intravenous form.56 Amphotericin B is used in the treatment of candidiasis,
aspergillosis, coccidiomycosis, blastomycosis, and cryptococcosis and is still the most potent
antifungal drug available with the broadest spectrum of activity of any systemic antifungal.
However, AmpB is toxic to the kidneys through a mechanism presumed to involve
tubuloglomerular feedback. This kidney toxicity can be reduced by administering sodium
chloride, which suppresses glomerular filtration.56 Additional side effects include hypokalemia,
hypomagnesemia, and bone marrow suppression.57 Lipid formulations of AmpB have been
developed in an attempt to alleviate some of the toxic side effects and amphotericin B lipid
complex (ABLC) and liposomal amphotericin B (L-AmB).58 ABLC is larger in size and is
quickly taken up by macrophages where it is kept in the liver and spleen.58 L-AmB has a smaller
size and a negative charge which prevents recognition by the mononuclar phagocyte system, and
it is sequestered in the liver and spleen as well.58 Despite modification, L-AmB has been shown
to have a similar nephrotoxicity as the original formulation and has been associated with
hepatotoxicity.59 Both lipid formulations have been associated with inducing infusion reactions
such as chills, fever, nausea, and vomiting.59 In trials done looking at renal toxicity, the lipid
formulations have better outcomes than AmpB58. However, one study comparing the two lipid
formulations found L-AmB to have greater renal insufficiency and more incidences of chronic
kidney disease as compared to ABLC, but ABLC patients experienced acute kidney injury more
often resulting in discontinuation of therapy.59
Other commonly recognized polyenes include nystatin and natamycin. Nystatin is used to
treat cutaneous or mucocutaneous mycotic infections caused by Candida species.60 Natamycin is
typically used to treat fungal eye infections. While most other polyenes work by causing
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alteration in fungal plasma membrane permeability, natamycin works by binding to ergosterol
and preventing ergosterol-dependent membrane fusion and fission, especially for vacuolar
compartments.61 Natamycin is derived from Streptomyces natalensis and is fungicidal in a dosedependent manner. 61, 62
Flucytosine
Flucytosine is an analogue of the nucleic acid pyrimidine and is converted by fungal
cytosine deaminase to 5-fluorouracil that blocks RNA and DNA synthesis.63 Flucytosine is water
soluble and well absorbed after oral administration.57 Due to the high likelihood of fungi to have
either innate or acquired resistance to the drug, flucytosine is often used in combination with
Amphotericin B to treat Cryptococcus, disseminated candidiasis, and aspergillosis and
sometimes with azoles for the treatment of cryptococcal meningitis and other mycoses.57
Azoles
Azoles were introduced in the 1970s and are characterized as having five membered
organic rings that include nitrogen. They function by inhibiting lanosterol 14-a-demethylase
(Erg11), an enzyme that localizes to the endoplasmic reticulum and is unique to fungal cells.64
Erg11 is responsible for converting lanosterol to ergosterol, a vital sterol found in the fungal cell
membrane. Azoles are fungistatic as they only inhibit further growth of the fungi. This drug class
is typically divided into either imidazoles or triazoles based on minor differences in chemical
structures: imidazoles contain two nitrogen molecules while triazoles have three.56 Imidazoles
are used for localized superficial infections such as those found in the mouth, vagina and on the
skin, while triazoles are used for invasive, life-threatening fungal infections. Triazoles include
the most commonly known and prescribed drug for Candida infections, fluconazole, a water7

soluble compound that is extremely effective in cases of fungal meningitis as it can penetrate the
blood-brain barrier and is the first line of defense against candidemia in nonneutropenic
patients.57, 65
Allylamines
Allylamines, like azoles, inhibit ergosterol biosynthesis and therefore induce cell
membrane permeability. Allylamines inhibit of squalene epoxidase, an enzyme involved in the
conversion of squalene into lanosterol, which is then converted into ergosterol. The inhibition of
this enzyme changes the cell membrane permeability leading to fungal cell lysis. Fungal
squalene epoxidase is sufficiently divergent from mammalian enzymes that allylamines are
considered selective for ergosterol biosynthesis without significantly inhibiting cholesterol
production in humans. An example of a synthetic allylamine that was introduced in the 1990s is
terbinifine, sold commercially as Lamasil. Terbinifine is freely soluble in methanol,
dichloromethane, and ethanol, and is slightly soluble in water. It is used in the treatment of
fungal infections of the skin and nails including ringworm, jock itch and athlete’s foot.66, 67
Terbinafine is available in either an oral formulation or a cream. Side effects include
gastrointestinal, central nervous system or neurological, hepatic, immune system, psychological,
sensory and skin problems. Another synthetic allylamine commercially available under the brand
name Exoderil or Naftin gel, is naftine. It is used to treat superficial dermatophyte fungal
infections including those found on the arms, legs, feet, and the groin.68
Echinocandins
The early 2000s ushered in the last of the new antifungal drug classes that have been
added to the clinical treatment arsenal with the introduction of echinocandins. Echinocandins
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inhibit 1,3-beta-glucan synthase (Fks1), an enzyme required for the production of cell wall
glucans. These polysaccharides play a major role in the structure of the fungal cell wall and are
not present in mammals. Inhibition of Fks1 activity leads to a loss of cell wall integrity, which
ultimately leads to osmotic instability and cellular lysis. With a broad spectrum of fungicidal
activity against yeasts, fungistatic activity against molds such as A. fumigatis69, and limited drugdrug interactions, echinocandins have become the first line of treatment for hospital-acquired
candidemia and invasive candidiasis. These semisynthetic lipopeptides are soluble in water and
have been widely used due to the fact that their biological target has no mammalian counterpart.
Echinocandins currently used in the clinical setting include micafungin, anidulafungin, and
caspofungin. Micafungin is used to treat candidemia and esophageal candidiasis and is
intravenously administered. Clinical trials have shown that micafungin is metabolized by P450
enzymes in the liver which can lead to liver damage.70
Resistance to current clinical antifungals
Candida species resistance to antifungals can either be intrinsic (primary acquisition) or
acquired (secondary acquisition).69 Intrinsic resistance has been found to occur naturally within
some fungi even with no previous exposure to antifungals, and often use the same resistance
mechanisms seen in acquired resistance.69 Exposure to antifungals as a result of clinical
prophylaxis, long term therapy or repeated drug dosing is associated with the emergence of
resistance.69 Drug resistance can also be the result of suboptimal drug exposure either as a result
of poor patient compliance with drug dosing or the inability of the drug to reach the site of
infection at an optimal dosage due to its location.69 There are several well defined resistance
mechanisms of Candida species to the currently available clinical antifungals including
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decreasing effective drug concentrations, target alterations, and alterations in metabolic
pathways.71
Decreasing effective drug concentrations
Upregulation of efflux pumps is the most common mechanism of resistance found for
azoles. These small molecule exporters are encoded by genes of the plasma membrane localized
ATP-Binding Cassette (ABC) or Major Facilitator Superfamily (MFS).69 Upregulation of these
transporters can be mediated by mutations in gene regulators that confer a hyperactivated state,
thereby causing inherent high transcriptional expression levels of transporter genes.69
Target alterations
Target alterations, or mutations in the drug target, are mainly found to impact azoles and
echinocandins. Erg11, the target of azole activity has been shown by X-ray structure to have
water-mediated hydrogen bonding between tyrosine at amino acid position 140 and fluconazole.
Point mutations that change this tyrosine to either a histadine or phenylalanine have been shown
to lead to resistance.69 Alterations that increase the drug target have also been found to lead to
antifungal resistance. In these cases, target gene overexpression can result from ploidy issues,
gene duplication events, or enhanced transcriptional regulation. High genomic plasticity,
including loss of heterozygosity, increase or decrease in chromosomal copy number, aneuploidy
and isochromosome formation, can alter expression of the drug target, efflux pumps, or both.69
One study found that aneuploidy in general and the specific duplication and deletion events
associated with isochromosome formation of chromosome 5 are associated with azole
resistance.72 Overexpression of Erg11 in C. albicans can also be caused by gain of function
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mutations in Upc2, a zinc-cluster transcriptional regulator of ERG11. These gain-of-function
mutations in UPC2 increase ERG11 expression thereby decreasing fluconazole susceptibility.73
Echinocandin resistance results from mutations in FKS genes which encode glucan
synthase. Amino acid substitutions occur in Fks1 in C. albicans and in Fks1 or Fks2 of C.
glabrata, where both are required for catalytic activity.74, 75 The most prominent substitutions
occur at serine residues at positions 641 and 645, which together account for 90% of resistance
in C. albicans.69, 76, 77 Although the biochemical mechanism is currently unknown, these target
alterations confer a 50- to 3,000-fold decrease in sensitivity to echinocandins.78
Resistance to polyenes is rare as they act through a physiochemical mechanism rather
than an enzymatic pathway, but resistance can develop.71 As polyenes act in part by binding to
plasma membrane ergosterol, a reduction in ergosterol levels can lead to reduced bioactivity of
this antifungal agent. This can be conferred by prior azole usage, as azole exposure will cause
lower cellular sterol concentrations.79 Mutations that inhibit or reduce sterol biosynthesis can
also lead to resistance, which can include mutations throughout the ERG pathway.80
Metabolic pathways
Resistance can also be conferred with the acquisition of mutations that alter the metabolic
pathway targeted by the antifungal such as that identified for azole resistance and ERG3
mutations. In this case, mutations in Erg3 prevent the conversion of the precursor substrate of
Erg11 into a toxic product, which creates resistance to azoles due to a build-up of 14amethylfecosterol and cross resistance to AmpB due to a loss of ergosterol biosynthesis.
Sequencing of an azole resistant clinical isolate showed there to be a two nucleotide deletion
leading to a truncated and nonfunctional Erg3p enzyme.81, 82 A study done by P.F. Watson et al,
concluded that functional Erg3 (C5-6 desaturase) is required for synthesis of 14-methyl-3,6-diol
11

(which confers susceptibility to azoles) under conditions that inhibit Erg11. This mechanism of
action is based on the inability of 14-methyl-3,6-diol to support growth. Growth occurs in
utilization of 14a-methylfecosterol produced by a combination of azole inhibition of Erg11 and
defective Erg3.44
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Lanosterol

ERG25,
ERG26,
ERG27

ERG6

Obtusifoliol
ERG25,
ERG26,
ERG27

Eburicol
Sterol 14!-demethylase
(ERG11)
Target of azoles

14!-methyl fecosterol
Sterol ∆5, 6 –desaturase
(ERG3)

4, 4 Dimethyl-ergosta
8, 14, 24 (28)-trienol

14!-methylergosta8, 24(28)-dien-3ß, 6!-diol
Toxic product

ERG24, ERG25,
ERG26, ERG27
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Episterol
Sterol ∆5, 6-desaturase
(ERG3)
Ergosta 5, 7, 24 (28)-trienol
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Ergosterol
Target of polyenes
Ergosterol biosynthesis pathway
A schematic showing the biosynthesis pathway for ergosterol in Candida albicans. Dashed lines
represent multiple enzymatic steps. Image derived from information in Figure 1 from Martel, et.
al.83
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There has not been a new drug clinically available on the market to treat fungal infections
since the echinocandins were introduced in the early 2000s. However, there are numerous drugs
in the pipeline being studied or tested for commercialization. Many of these drugs are modified
versions of currently available ones. Although these modifications aim to reduce toxicity and
associated side effects, they will not combat the problem associated with fungal resistance.
Given this increase in resistance, the drugs focused on here will be ones that are being developed
to treat Candida infections with novel mechanisms of action or drugs with new initiatives using
old drug targets.
New initiatives with old drug targets
SCY-078 (Ibrexafungerp)
The natural product, enfumafungin, is a glycosylated fernane-type triterpenoid produced
by the endophytic fungus Hormonea carpetanum and isolated from the evergreen leaves of
Juniperus communis.84, 85 Enfumafungin has derivatives that inhibit fungal glucan synthase,
however, they are structurally different from that of echinocandins and therefore they constitute a
new class of glucan synthase inhibitor. SCY-078 is a semisynthetic derivative of enfumafungin
that consists of a terpene cyclase domain fused to a glycosyltransferase domain, representing a
novel multifunctional enzyme. SCY-078 is formulated for either oral or intravenous delivery. It
has shown in vitro and in vivo activity against echinocandin- and azole-resistant Candida isolates
and has been determined to be fungicidal.86, 87 Further clinical phase testing will be needed to
determine the efficacy of SCY-078. Additionally, SCY-078 was tested on Candida auris
biofilms and was found to significantly reduce metabolic activity and thickness as well as
reduced fluorescence with concanavalin A staining.88 Ibrexafungerp is currently undergoing
clinical trials including, a phase II study looking to “Evaluate the Safety and Efficacy of the
14

Combination Therapy of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive
Pulmonary Aspergillosis (SCYNERGIA)”, and a phase III trial to study the “Efficacy and Safety
of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal
Candidiasis”.89
CD101 (Rezafungin)
Rezafungin, considered a novel echinocandin, is a 6-amino cyclic peptide with a
lipophilic group derived from anidulafungin. Rezafungin has been shown to have dosedependent fungicidal activity.90, 91 Compared to other echinocandins, it has increased in vitro and
in vivo stability, a longer half-life allowing for once-weekly dosing, and is active against early
and mature Candida albicans biofilms.90, 92 Rezafungin has a favorable safety profile.90 One
study showed that it was potent against multiple strains of Candida auris, including some strains
that were previously identified to be resistant to other echinocandins.93 Rezafungin has
completed several clinical trials including: two phase I trials looking at a single ascending dose
and a multiple ascending dose, a phase II trial looking at CD101 compared “Standard of Care in
Subjects With Acute Yeast Vaginal Infections”, and a phase II follow up trial entitled “NonInterventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida
Colonization”. Currently, it is in two clinical trials: a phase II trial entitled “CD101 Compared to
Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive
Candidiasis-Bridging Extension (STRIVE)” and a phase III trial entitled “Study of Rezafungin
Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
(ReSTORE)”.89
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VT-1161, VT-1129 (Quilseconazole), & VT-1598
One of the biggest problems facing current clinically available azoles is drug-drug
interactions. To address this issue, Viamet Pharmaceuticals Inc. has created three new drugs
from modified azoles that have greater specificity for the fungal Cyp51 enzyme, responsible for
converting lanosterol to ergosterol, than for mammalian homologue CYP 450 enzymes. All three
drug modifications have shown fungistatic efficacy against Candida species and against some
azole resistant strains.94,95, 96 VT-1161 passed a phase 2 study showing efficacy against recurrent
vulvovaginal candidiasis in November of 2016.89, 97 Three additional phase II clinical trials were
completed to evaluate the safety and efficacy of oral VT-1161, one in patients with acute vaginal
candidiasis, one in patients with moderate to severe interdigital althlete’s foot, and one in
patients with onychomycosis of the toenail (dermatititis).89 Currently there are three phase III
clinical trials in the recruiting stage to evaluate oral VT-1161 for the treatment of patients with
recurrent vaginal candidiasis (two identical studies) and for the treatment of acute vaginal
candidiasis in patients with recurrent vaginal candidiasis.89
VT-1129, aka Quilseconazole, has shown in vitro activity against Cryptococcus
neoformans, Cryptococcus gatti, Candida glabrata, and Candida krusei isolates clinically
resistant to azoles and echinocandins.98, 99 In June of 2016, Viamet Pharmaceuticals, Inc.
announced that the FDA had granted Fast Track designation for VT-1129 for the treatment of
cryptococcal meningitis and that it has also received Orphan Drug designation as well as been
designated a Qualified Infectious Disease Product by the FDA.100 In preclinical experiments, the
drug was shown to completely remove the fungal burden of cryptococcal meningitis from the
brain, which to date is the only drug known to do so.99, 100
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iCo-010
Amphotericin B (Amp B), the first line of defense in systemic fungal infections, has two
main drawbacks to its use: associated nephrotoxicity and the limitation of only being available in
an intravenous formulation. Multiple oral formulations of Amp B have been investigated
including carbon nanotubes, cochleates (stable particles derived from liposomes, composed
mainly of phosphatidylserine), and lipid-based formulations. While carbon nanotubes showed
promise in a hamster model, they remain unknown in humans.101 A cochleates formulation of
AmpB was effective against candidiasis in a murine model, but took 15 days of treatment to
reduce fungal burden in target organs.101 One lipid-based formulation, iCo-010, has shown
enhanced solubility, absorption, reduced nephrotoxicity and stability at tropical temperatures,
where oral formulations of Amp B are desperately needed. iCo-010 treated acute systemic
candidiasis in a rat model in a dose-dependent manner after two days.101 According to the
company that owns iCo-010, iCo Therapeutics Inc., they are currently conducting a phase I
clinical trial in Australia studying doses of iCo-010 at 100, 200, 400 and 800 mg in human
patients. A sufficient drug supply is available for a proposed mid-stage clinical trial with
increased patient numbers to investigate the efficacy and safety of the oral AmpB formulation.102
New peptide based therapeutics
P-113 (PAC-113), P-113Du, and P-113Tri
A potent antimicrobial peptide found in saliva, Histatin 5 shows efficacy against Candida
albicans. P-113 is a 12 amino acid peptide derived from Histatin 5. The salt sensitivity of P-113
necessitated the generation of two derivatives, P-113Du and P-113Tri. These variants improved
efficacy in high salt and in low pH environments as well as candicidial activity against
planktonic and biofilm cells, including clinical isolates of multiple Candida species.103, 104
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Against fungal biofilms, P-113Tri was most effective followed by p-113Du and P-113. The
mechanism of action of P-113 has been determined to be through interactions with fungal cell
membranes, altering permeability and causing cytoplasmic leakage. Based on hemolytic activity,
all three derivatives also showed low cytotoxicity.103 Pacgen, the company that owns these drugs,
has a worldwide license to develop and commercialize P113. They also have a sublicense giving
rights to General Biologicals Corporation for a non-prescription over-the-counter line of
products containing the drug. The line includes an oral rinse, feminine wash products, and antibacterial hand cream. The products are available in Taiwan or can be purchased online via their
website.104
NP339 (Novamycin)
NP339 is in development as an inhaled, systemic and mucocutaneous therapy. It is a
quick acting fungicidal poly-Arginine based cationic peptide. Novamycin is derived from the
already commercially available drug, Novexatin, a novel cationic antifungal peptide used in the
treatment of onychomycosis (fungal nail infection), so there is less risk for Novamycin on the
clinical route. The mechanism of action of Novamycin is through membrane perturbation and
lysis. There is minimal risk of acquired drug resistance as it quickly kills both non-metabolizing
and metabolically active fungi, particularly those caused by Aspergillus spp. and Candida spp.105,
106

A press release in February 2019 by the company that owns Novamycin, NovaBiotics, claims

that they have been awarded a grant that will help transform the drug from a laboratory stage
antifungal compound to a drug ready for clinical testing.107
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PLD-118 (Icofungipen or BAY 10-8888)
Icofungipen is a b-amino acid that inhibits fungal isoleucyl-tRNA synthetase resulting in
a reduction in charged tRNAILE, a halt to protein synthesis, and ultimately inhibition of fungal
cell growth.108, 109 It is a cyclic b-amino acid, which differs from any current antifungal class.109
The drug was isolated from the broth of a strain of Bacillus cereus. It is water soluble and
amphoteric.110 Icofungipen has shown good efficacy against Candida spp. in mice, however
phase II clinical trials were discontinued as it was found in human toxicity studies to cause a
suppression of spermatogenesis in male subjects.108 A 2017 paper reviewing Icofungipen has
suggested that modifications to the drug need to be explored to find less toxic variations as it
showed great efficacy in vivo.108
hLF1-11
Human lactoferrin (hLF) is a 692 amino acid iron binding glycoprotein that is
synthesized by mucosal gland epithelial cells and neutrophils in response to inflammation.111
Proteolytic cleavage of hLF generates a 47 amino acid fragment, lactoferrin H. This amino
terminal peptide includes two cationic domains residues 2-5 and 28-31. A synthetic peptide
compromised of this first cationic domain, referred to as hLF1-11, exhibits both antibacterial and
antifungal activity. This antimicrobial activity combined with its ability to stimulate macrophage
and dendritic cells, contributes to the clearance of infections resulting in enhanced in vivo
activities.111 It has previously been shown to be nontoxic against human red blood cells and was
well tolerated by healthy volunteers. hLF1-11 significantly inhibits early C. albicans biofilm
formation by affecting the yeast-hypha transition.111 hLF1-11 completed a dual phase I and phase
II clinical trial in November of 2006 looking at a single dose of 5 mg given to autologous
hematopoietic stem cell transplant recipients. Three other dual phase I and phase II trials were
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withdrawn citing reasons for either a strategic company decision, patient population not being
available, or the recruitment not being feasible within the timeframe.89
Occidiofungin
Occidiofungin is a natural product nonribosomally synthesized by the soil bacterium
Burkholderia contaminans MS14, and was discovered in a green grassy area that was
suppressing surrounding brown patch disease.112-114 It is a cyclic glycolipopeptide comprised of
eight amino acids, an 18-carbon fatty acid and a xylose group, is fungicidal in activity, and has
been shown to be effective against multiple Candida species including C. albicans and C. auris,
as well as isolates shown to be resistant to fluconazole and caspofungin.112, 115, 116 In a murine
model, occidiofungin demonstrated effectiveness in treating a vulvovaginal yeast infection, and
had little to no side effects when administered by intraperitoneal and subcutaneous injections.113,
117

In follow up studies, occidiofungin was shown to have low cytotoxic activity when evaluated

following a 5 mg/kg intravenous tail vein injection, as well as against human fibroblast and
cancer cell lines. Interestingly, occidiofungin appeared to preferentially target cancerous
mammalian cells with dosages even lower than those required for treating candidiasis.113
Histology, hematology, and blood serum chemistry also did not reveal significant signs of
toxicity.113 The biological target of occidiofungin has recently been identified as actin based on
its highly specific localization to cellular regions rich in actin in yeast and its binding to purified
actin in vitro.116
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Drugs with novel biological targets
APX001
APX001 is a prodrug that is processed by alkaline phosphatase to produce the
biologically active drug APX001A (formerly E1210).118 APX001A inhibits glycosyl
phosphatidylinositol (GPI) production which ultimately prevents the attachment of integral
adhesion proteins to the extracellular matrix side of the plasma membrane. Specifically,
APX001A inhibits the activity of Gwt1 (GPI-anchored wall transfer protein 1), the enzyme
responsible for the conversion of glucosaminylphosphatidyl inositol to its acrylate form,
glucosaminyl(acyl)phosphatidyl inositol.119, 120 The absence of this post-translational
modification results in reduced levels of GPI-anchored proteins including those involved in
providing pathogenicity and immune system protection, cell wall integrity, cell-cell adhesion,
and fungal membrane homeostasis. APX001 is a promising new drug as it has inhibited the
inositol acylation activity of Gwt1p of Candida albicans, Candida auris, Cryptococcus, and A.
fumigatus but has no inhibitory effects against the human orthologue Pig-Wp, even at high
concentrations.118 It is also fungicidal and can be used as a supplemental or synergistic drug with
other antifungal drugs such as azoles or echinocandins.121 APX001 is currently in a Phase II
clinical trial “An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With
Candidemia” and is expected to be completed in August 2020.89
NDV-3A
The C. albicans agglutinin-like sequence 3 protein (Als3p) has been selected as a vaccine
antigen for reoccurring vulvovaginal candidiasis (RVVC) based on its role as an invasin,
enabling penetration of host cell tissues, and an adhesin, promoting fungal attachment to biotic
and abiotic substrates.122, 123 Virulence factors of C. albicans are greatly impaired when the ALS3
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gene is deleted.122 It is reported that the mechanism of protection against hematogenously
disseminated candidiasis in mice was primarily mediated by activation of Th1/Th17 immune
responses.124 A phase II study has shown the NDV-3A vaccine elicits this immune response
which protected patients younger than 40 with a history of recurrent vulvovaginal candidiasis
from recurrence over a 12 month period.122 The phase II study was completed in May 2016 and
looked at “Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing
Recurrent Vulvovaginal Candidiasis”. A second phase II study is currently being done looking at
“Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization” and is estimated to be
completed in September of 2019.89
PEVION7 (PEV7)
PEVION7 (PEV7) is a vaccine used to treat recurrent vulvovaginal candidiasis (RVVC).
It is made using secretory aspartyl proteinase (Sap2), a recombinant protein that serves as a
virulence factor of C. albicans as it has both enzymatic activity, degrading cell surface proteins
on host cells rendering them unable to elicit an immune response, and inducing pathogenic
inflammation of host cells, independent of enzymatic activity. Sap2 belongs to a family of at
least ten enzymes that are present in C. albicans and other pathogenic eukaryotes, yet are also
highly conserved among retroviruses. This is an extremely valuable characteristic as it can be
used as a recombinant protein in the creation of the vaccine.125, 126, 127 A phase I study was
completed in December of 2012 looking at the safety and immunogenicity of the virosomal
vaccine against recurrent vulvovaginal Candida infection.89
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Mul-1867
Mul-1867 is a newly synthesized polycationic drug developed by TGV Laboratories. As
an inhalant, Mul-1867 targets mixed infections of yeasts, molds, and bacteria of the respiratory
tracts of immunocompromised patients.128, 129 In a 2017 study, Mul-1867 exhibited efficacy
against non-resistant organisms and multi-resistant clinical isolates from patients. It was also
effective against fungal biofilms. Mul-1867 was found to be a membrane permeability altering
agent and was shown to be fungicidal against yeasts and molds.128 According to multiple news
releases, Mul-1867 was granted Orphan Drug Status by the FDA in 2016 for the treatment of
antibiotic-resistant bacterial lung infections in cystic fibrosis patients.130, 131
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YEAST SCHEMATIC SHOWING FUNGAL TARGETS OF PIPELINE DRUGS
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A schematic showing the targets of pipeline drugs in a generalized yeast cell.
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Conclusion
Fungal resistance to the four classes of currently available clinical antifungals continues
to rise. With no new drugs having been introduced to the market since the early 2000s, it is
crucial that new drugs be made available to combat resistant fungal strains. There are countless
new and promising drugs being developed and screened in the pipeline. Of the pipeline drugs
discussed, there are six that have targets unique to fungi, including: VT-1161, VT-1129 and VT1598 (ergosterol biosynthesis pathway), SCY-078 and CD101 (cell wall integrity pathway), and
iCo-10 (membrane ergosterol). Four are general membrane disruptors: Mul-1867 (also targets
bacteria), P-113Du and P-113Tri, and NP3339. Three elicit host immune responses: NDV3,
PEV7, and hLF-11 (also targets bacteria), and three have targets common to mammalian cells,
but with higher affinity for fungi: APX001 (GPI), PDL-118 (tRNA synthetase), and
occidiofungin (actin). All of these new drugs bring hope and promise to the future of combating
fungal infections in the clinical setting by providing a much larger arsenal of drugs to effectively
treat patients.
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Abstract
Occidiofungin is a cyclic glyco-lipopeptide produced by Burkholderia contaminans.
Minimum inhibitory concentrations (MICs) against Candida species were between 0.5 and 1.0
µg/mL. Occidiofungin retains its in vitro potency in the presence of 5% and 50% human serum
with a minimal lethal concentration (MLC) of 2 and 4 µg/mL, respectively. Time-kill and postantifungal effect (PAFE) experiments of occidiofungin against Candida albicans were measured.
These results demonstrate that occidiofungin is fungicidal. Occidiofungin was also found to be a
very stable molecule. It is resistant to extreme temperatures and pH, and maintains its activity
following exposure to gastric proteases.
Introduction
Novel antifungals are needed because of the importance of fungal infections in organ
transplant patients, and the limitations of currently available antifungal agents regarding their
spectra of activity and toxicities. Furthermore, there is a demand for new antifungals, given the
prevalence of azole-resistant fungal pathogens.1, 2 There are four major therapeutic groups of
antifungal agents: polyenes, azoles, allylamines, and the echinocandins. The first three groups
primarily target ergosterol production or bind to ergosterol, disrupting the fungal membrane.3-5
Ergosterol, much like cholesterol found in mammalian cells, is important for maintaining proper
cell permeability and fluidity. The echinocandins, the fourth group, are synthetically modified
lipopeptides that originate from the natural compounds produced by fungi.6, 7 The antifungal
activity of echinocandins is attributed to selective inhibition of 1,3-b-glucan synthesis by
functioning as a non-competitive inhibitor of 1,3-b-glucan synthase.8-12 There is a need to
identify unique antifungals for possible development of new therapeutics.
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Occidiofungin is an antifungal peptide produced by the bacterium Burkholderia
contaminans MS14. This bacterial strain was isolated from soil that suppressed brown patch
disease of lawn grass. A substantial amount of work has been done to characterize the genetic
locus and regulatory elements of the antifungal compound.13-15 Structural characterization
determined that occidiofungin is a cyclic glyco-lipopeptide.13, 16 Four structural variants of the
antifungal peptide, named occidiofungin A-D, have been identified. They have a mass of
1,200.39 Da, 1216.41 Da, 1234.17 Da, and 1250.41 Da, which corresponds to the addition of
oxygen and/or chlorine to the first compound. The target and the "mechanism of action" of
occidiofungin are still unknown. The antifungal has been shown to inhibit a wide array of fungi
16

, such as Alternaria alternata, Aspergillus fumigatus, Aspergillus niger, Fusarium oxysporum,

Geotrichum candidum, Macrophomina phaseolina, Microsporum gypseum, Penicillium sp.,
Rhizoctonia solani MSCOT-1, and Trichophyton mentagrophytes. In addition, two Pythium
species were sensitive at nanomolar concentrations: Pythium spinosum and Pythium ultimum. In
this study, we tested the sensitivity of Candida species to occidiofungin with and without the
presence of human sera. We also performed simultaneous time kill curves and post-antifungal
effect (PAFE) experiments on C. albicans (ATCC 66027). Lastly, we tested occidiofungin's
chemical stability against extreme pH and temperature, as well as its stability against gastric
proteases.
Methods
In vitro susceptibility testing
Occidiofungin was purified as previously described.14 Microdilution broth susceptibility
testing was performed in duplicate according to the CLSI M27-A3 method in RPMI 1640
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(buffered to a pH of 7.0 with MOPS (morpholinepropanesulfonic acid)) growth medium. 100X
stock solutions of occidiofungin were prepared in dimethyl sulfoxide (DMSO). MIC endpoints
for occidiofungin were determined by visual inspection and were based on the wells that had no
visible growth (an optically clear well) after 24 hours of incubation. Susceptibility testing was
done in duplicates. DMSO containing no antifungal agent was used as a negative control.
Serum MICs
Susceptibility testing, as described above, was performed in duplicate according to the
CLSI M27-A3 method in RPMI or YPD growth medium in the presence of 5% and 50%
(vol/vol) human sera (Sigma Aldrich, St. Louis, MO). Given the turbidity of 50% serum, 50 µL
of cell suspension in each well of the microtiter well was plated to determine the minimum lethal
concentration (MLC). MLC is the well that has fewer than 10 viable cells (colonies) in the 50 µL
spread on the plate.
Time-kill experiments and PAFE
Time-kill experiments and PAFE were done according to a method reported by Clancy et
al.17 Candida albicans (ATCC 66027) colonies on 24-hour old YPD plates were suspended in 9
mL of sterile water. The density was adjusted to a 0.5 McFarland standard,17-21 and was diluted
10-fold with RPMI 1640 medium to a final volume of 10 mL containing a final concentration of
16, 4, 2, 1, and 0 µg/mL of occidiofungin. The cultures were incubated at 35ºC with agitation.
For the time-kill experiment, 100 µL samples were drawn, serially diluted, and plated on YPD
for colony counts. PAFE experiments were performed in a similar manner, except that following
a one-hour exposure to the antifungal compound, the cells were pelleted (1400 g for 10 min),
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washed three times and resuspended with 10 mL of pre-warmed (35ºC) RPMI 1640, and then
returned to 35ºC. Similarly, 100 µL samples at times 0, 2, 4, 8, 12, and 24 hours were drawn and
plated for counting colony forming units (CFU). Each experiment was completed at least twice
for each sample.
Temperature stability
Occidiofungin was brought up in 0.5 mL of DMSO at a concentration of 400 µg/mL.
Subsequently, 60 µL (24 µg) was added to 540 µL of 0.1 M sodium phosphate buffer (pH 7.0) in
a 1.8mL eppendorf tube. Each tube was then placed in a water bath at 50, 60, 70, and 100˚C for
30 minutes. Then, 200 µL from each tube was added to the first well of each row of a 48 well
microtiter plate and serially diluted two-fold in 100 µL of RPMI. Lastly, C. albicans (ATCC
66027) suspension was prepared using the CLSI protocol described above and 900 µL was added
to each well. A negative control was made by combining 1 mL DMSO to 9 mL of 0.1 M sodium
phosphate buffer, and subsequently treated in the same manner as the occidiofungin samples.
The microtiter plate was placed in the incubator for 24 hours at 35˚C. MIC was determined as
described above.
pH stability
Occidiofungin (160 µg) was dried down into eight separate 1.8 mL eppendorf tubes
labeled from pH 2 to pH 9. The dried samples were resuspended in 1 mL of RPMI 1640. Using
stock solutions of 6 M HCl and 6 M NaOH, the pH of the samples were adjusted accordingly and
then left at room temperature for two hours. After two-hour exposure, the pH was readjusted to
pH 7.0. The 160 µg/mL solution was subsequently diluted two-fold, resulting in concentrations
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of 160, 80, 40, 20, 10, 5, and 2.5 µg/mL. Using a 48 well microtiter plate, 100 µL of antifungal
solution from each of these tubes was added to its corresponding well. A suspension of C.
albicans (ATCC 66027) following the CLSI methodology described above was prepared and 900
µL of the suspension was added to each well containing the antifungal solution. MICs were
determined as described above.
Protease stability
Occidiofungin's stability was tested against the digestive proteases trypsin, chymotrypsin,
and pepsin. For the trypsin assay, a 2X stock solution of sodium phosphate buffer (0.134 M, pH
7.6) and a 10X trypsin stock solution (5.19 mg of trypsin in 1 mL of a 1 mM HCl solution) was
used. For the chymotrypsin assay, a 2X stock solution of Tris buffer containing calcium chloride
(200 mM Tris HCl and 20 mM calcium chloride, pH 8.0) and a 10X chymotrypsin stock solution
(5.6 mg of chymotrypsin in 1 mL of 1 mM HCl, 2 mM calcium chloride) was used. For the
pepsin assay, a 2X stock solution of 20 mM HCl and a 10X pepsin stock solution (0.8 mg of
pepsin in 1 mL of sterile deionized water) was used. The reaction mixtures having a final volume
of 250 µL were prepared and consisted of 25 µL 10X protease stock solution, 125 µL of 2X
stock solution, 97.5 µL of sterile water, and 2.5 µL of DMSO. Then, 100 µL of the reaction
solution was added to two 1.8 mL eppendorf tubes containing 8 µg of occidiofungin and
incubated at 35ºC for 30 minutes. A suspension of C. albicans (ATCC 66027) following CLSI
methodology described above was prepared and 900 µL of the suspension was added to each
tube containing the antifungal solution and incubated for 4 hours at 35ºC. CFUs were measured
after 4 hours of incubation by serially diluting and plating. The plates were incubated at 35 ºC for
24 hours and CFUs were determined. The assays were repeated for a 60- and 120-minute
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exposure to the gastric proteases. Controls consisted of 10X stock solutions containing no
protease, no occidiofungin, and protease inhibitors for trypsin (phenylmethanesulfonylfluoride;
PMSF), chymotrypsin and pepsin (0.5µM E-64, 0.1 µM Leupeptin, 0.7µM Pepstatin A, 0.6µM
Bestatin, 37.5uM AEBSF, 1mM PMSF, and 3U Trasylol). Each experiment was completed in
duplicate.
Protease activity of trypsin, chymotrypsin and pepsin was confirmed using bovine serum
albumin (BSA) as the substrate in place of occidiofungin in the reactions described above at a
final concentration of 4.4 µg/µl. After 0, 30, 60 and 120 minutes at 35˚C, 20 µL aliquots were
removed and the reaction stopped by adding 80 µL of SDS loading buffer. A volume equivalent
to 4 µg of BSA was electrophoresed on a 12% SDS-PAGE and proteins visualized by Coomassie
Blue staining.
Results
Susceptibility testing
The MIC against two Candida albicans strains and a strain of C. glabrata was 0.5 µg/mL
(Table 1). The MIC for a C. albicans 66027, C. tropicalis and C. parapsilosis was determined to
be 1.0 µg/mL. The most direct approach to determine the effect of protein binding on the
antifungal activity of occidiofungin is to test the compound in the presence of serum. This
provides information as to the amount of unbound antifungal compound that is present in blood.
This information is also important for future formulations for efficacy studies in an animal
model. Serum MICs were determined using 5% and 50% human serum (Sigma Aldrich, St.
Louis, MO; vol/vol) in YPD medium (Table 2), because C. albicans (ATCC 66027) and C.
glabrata (ATCC 66032) would not grow in the presence of 50% serum in RPMI 1640 medium.
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Given the turbidity of 50% serum, 50 µL of cell suspension from each well of the microtiter
plate was plated to determine the minimum lethal concentration (MLC). Activity of
occidiofungin was moderately inhibited by 5% and 50% human serum. The MIC at 5% human
serum was 1 µg/mL, while the MLC was determined to be 2 µg/mL for C. albicans (ATCC
66027) and C. glabrata (ATCC 66032). The MLC at 50% human serum was 4 µg/mL.
Presumably, the 2 to 4-fold reduction in activity in the presence of serum is attributed to protein
binding. A moderate decrease in activity in the presence of serum is not uncommon for
lipopeptides.22, 23
Time-kill and PAFE experiments
These experiments provide important information about the activity of occidiofungin.
These studies will determine whether or not occidiofungin is fungicidal or fungistatic, and its
rate of activity. The PAFE experiments will determine the relative effect occidiofungin has on
cells exposed for a short time period. This will provide information about the affinity
occidiofungin has to the cellular target and whether the antifungal activity can be washed away
following exposure. Time-kill assays are essentially a measurement of CFUs following the
addition of the antifungal to the yeast. The MICs for the time-kill experiments were 2 µg/mL at
24 hours (Figure 2A). The higher MIC is most probably attributed to the 2 to 3-log increase in
cell density compared to the cell density in the CLSI protocol. Time-kills revealed that
occidiofungin is fungicidal.18 There was a log decrease in cell density after 2-hour exposure with
1 times MIC and 2 times MIC concentrations, and a 2-log decrease in cell density following a 2hour exposure to occidiofungin with 8 times MIC. There was greater than a 3-log reduction by 8
hours and 24 hours with 8 times MIC and 2 times MIC, respectively. A 2-log decrease in cell
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density persisted for 24 hours with 1 times MIC dose. Interestingly, there appeared to be only a
moderate effect on the rate of growth at 0.5 times MIC in these experiments, but no reduction
from the starting inocula. This suggests that a threshold concentration is required for fungicidal
activity and that the fungal target needs to be saturated for effect. The rapid drop in cell density
after 2-hour exposure suggests that the target for occidiofungin is critical for survival, while the
slow gradual decrease in cell density post 2-hour exposure may be attributed to the chance that
these cells have not been saturated with occidiofungin, or possibly they were in a different
cellular growth phase that is less susceptible to occidiofungin's effects.
In the PAFE experiments, the fungicidal activity of occidiofungin at 2 times MIC was
washed away (Figure 2B). However, the effect of exposure was still visible 3 hours and 7 hours
after occidiofungin was removed at 1 times MIC and 2 times MIC, respectively. Moreover, 8
times MIC resulted in a greater than 3-log reduction in cells at 12 hours. The fungicidal effect of
a 1-hour exposure with 8 times MIC was permanent and was only delayed by 4 hours as
compared to the time-kill experiments. Presumably, occidiofungin has a strong interaction with
the fungal cells, given that three washes were not enough to eliminate its fungicidal activity at 8
times MIC. Another possibility is that occidiofungin may have an intracellular target. Irreversible
cellular damage following a 1-hour exposure is not probable given that viable cell counts were
present 7 hours after exposure in the PAFE experiments.
Chemical stability experiments
Occidiofungin was exposed to 50, 60, 70, and 100ºC for 30 minutes. In this temperature
stability experiment, the MICs of occidiofungin against C. albicans 66027 were 1 µg/mL for all
temperatures. This suggests that occidiofungin is stable following exposure to extreme
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temperatures. Occidiofungin was incubated at pH 2, 3, 4, 5, 6, 7, 8, and 9 for two hours. No loss
in antifungal activity against C. albicans 66027 was observed in this study. The MICs for all pH
samples were 1 µg/mL. Lastly, occidiofungin's stability against the gastric proteases trypsin,
chymotrypsin, and pepsin was evaluated (Figure 3). Occidiofungin's ability to kill following
exposure to each of these proteases for 30, 60, and 120 minutes was measured. The potency of
occidiofungin did not change following exposure to these proteases under the optimal condition
for their proteolytic activity. Presumably the cyclic nature of occidiofungin provides protection
against proteolytic cleavage.
Discussion
In vitro potency of occidiofungin against Candida species is in the sub-micromolar range,
and is not drastically inhibited by the presence of serum. The reduction in activity in the presence
of serum is similar to the reduction observed for anidulafungin.22 In addition, occidiofungin is
fungicidal against C. albicans, not fungistatic, and may provide a more aggressive treatment
option than from other conventional treatments. The initial 1 to 2-log drop in cell density
following exposure to occidiofungin is different from the time-kill and PAFE experiments
reported for caspofungin.17 The differences in activities in the time-kill and PAFE experiments
suggest that occidiofungin has a separate target from the lipopeptide caspofungin, and
presumably other echinocandins. These experiments support the need for efficacy studies aimed
at understanding occidiofungin's ability to treat systemic Candida infections.
Azoles are the only oral bioavailable drug for the treatment of fungal infections.
Lipophilic drugs generally have good colonic absorption, but caspofungin and anidulafungin oral
bioavailability is < 10%.24-26 Low oral bioavailability of caspofungin is attributed to drug
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permeability limitations to absorption.25 However, in the same study caspofungin is reported to
have some instability at an acidic pH. A detailed analysis of the chemical stability of
caspofungin, anidulafungin, or micafungin is not available. Occidiofungin is stable under
extreme temperature and pH. Furthermore, the compound is not inactivated by gastric proteases
trypsin, chymotrypsin, and pepsin. Given occidiofungin's chemical stability, studies aimed at
understanding occidiofungin's oral bioavailability are warranted.
Occidiofungin is a structurally unique antifungal peptide sharing homology to the
cepacidine A,27 and the recently discovered burkholdines.28 Occidiofungin is the first antifungal
from this group, to report its physical stability and in vitro activity against a human fungal
pathogen. These data suggest that further studies on occidiofungin and presumably other
antifungals within this small group of antifungals are necessary. These compounds may provide
a new line of treatment for life threatening fungal infections.
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Figures and tables
Table 1

Occidiofungin MICs
Isolate
C. albicans TE
C. albicans LL
C. albicans 66027
C. albicans 24067
C. albicans 11034
C. albicans 2677
C. glabrata 66032
C. glabrata 200989
C. glabrata 2001
C. tropicalis 66029
C. tropicalis 13803
C. parapsilosis 90018
C. parapsilosis 34136
C. parapsilosis 90875

MIC (µg/mL)
0.5
0.5
1.0
1.0
2.0a
1.0b
0.5
0.5
1.0
1.0
1.0
1.0
2.0
2.0

a. caspofungin resistant strain (MIC > 8 µg/mL)
b. fluconazole resistant strain (MIC > 64 µg/mL)

Table 2

Occidiofungin serum MIC/MLCs
Isolate
C. albicans 66027
C. albicans 66027

Percent Human
Serum
5%
50%

MIC/MLC*
(µg/mL)
1.0/2.0
4.0

C. glabrata 66032
C. glabrata 66032

5%
50%

1.0/2.0
4.0

* Only the MLC is reported, given the turbidity of 50% serum
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Kill curves for time-kill and post-antifungal effect
(A) Kill curves for time-kill (B) post-antifungal effect. Experiments on Candida albicans ATCC
66027. Symbols are as follows: □ 8 times MIC (16 µg/mL), ● 2X MIC (4 µg/mL), ▲ 1X MIC (2
µg/mL), ¨0.5X MIC (1 µg/mL), and ■ control (0 µg/mL).
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Bioactivity assay assessing proteolytic stability of occidiofungin and confirmation
of protease activity using BSA as a target substrate.
(A) Bioactivity assay assessing proteolytic stability of occidiofungin. Activity is reflective of the
CFU/mL. Occidiofungin (8 µg/mL) exposed to trypsin (black), chymotrypsin (gray), and pepsin
(white) for 30, 60, and 120 minutes. Control 1, control 2, and control 3 are reaction buffer with
protease, reaction buffer alone, reaction buffer with protease and with protease inhibitors,
respectively. (B) BSA was exposed to protease for 30, 60 and 120 minutes followed by
separation through a 12% SDS-PAGE gel. The first and last lanes are controls and contain BSA
in reaction buffer without added protease for 0 and 120 minutes, respectively.
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Abstract
Occidiofungin is a non-ribosomally synthesized cyclic peptide having a base mass of
1200 Da. It is naturally produced by the soil bacterium Burkholderia contaminans MS14 and
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possesses potent broad-spectrum antifungal properties. The mechanism of action of
occidiofungin is unknown. Viability, terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL), reactive oxygen species (ROS) detection, membrane and cell wall stability,
and membrane mimetic assays were used to characterize the effect of occidiofungin on yeast
cells. Confocal and electron microscopy experiments were used to visualize morphological
changes within treated cells. TUNEL and ROS detection assays revealed an increase in
fluorescence with increasing concentrations of the antifungal. Yeast cells appeared to shrink in
size and showed the presence of ‘dancing bodies’ at low drug concentrations (1µg/ml). A screen
carried out on Saccharomyces cerevisiae gene deletion mutants in the apoptotic and autophagy
pathways identified the apoptotic gene for YCA1, as having an important role in occidiofungin
response as cells deleted for this gene exhibit a 2-fold increase in resistance. Autophagy mutants
had no difference in sensitivity compared to the wild-type control. Results from our experiments
demonstrate that the mechanism of action for occidiofungin in yeast is different from that of the
common classes of antifungals used in the clinic, such as azoles, polyenes, and echinocandins.
Our study also indicates that occidiofungin causes cell death in yeast through an apoptotic
mechanism of action.

Introduction
Discovery and implementation of novel antifungal agents are needed for more effective
treatment of serious fungal infections.1 Antifungals currently used in the clinic do not meet the
growing needs of an increasing population of immuno-compromised patients due to limitations
in their spectra of activity and toxicities. Some current antifungal treatments lead to abnormal
liver function test and are primarily fungistatic. Discovery of novel antifungals with a broader
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spectrum of activity and lower toxicity are needed. There is a significant demand for new
antifungals given the prevalence of resistant fungal pathogens to conventional therapies.2, 3
Furthermore, identifying novel antifungals with a different mechanism of action from the current
class of therapeutically used antifungals may aid in the development of new and more effective
treatments.
There are three major therapeutic groups of antifungal agents used for the treatment of
serious fungal infections: polyenes, azoles, and the echinocandins. The first two groups primarily
target ergosterol biosynthesis or bind to ergosterol, disrupting the fungal membrane.4-6
Ergosterol, much like cholesterol found in mammalian cells, is important for maintaining proper
cell permeability and fluidity. These antifungals lead to an osmotic disruption of the cell
membrane, leading to an efflux of essential cellular contents resulting in cell death.
Echinocandins, the third group, are the newest fungal treatment option that has fairly recently (in
2003) entered the clinic. The echinocandins are synthetically modified lipopeptides that originate
from natural compounds produced by fungi and function to selectively inhibit b-1,3-glucan
biosynthesis.7, 8 In fungi, covalently cross-linked polysaccharides such as b-1,3-glucan, b-1,6glucan, and chitin form the primary scaffold that is responsible for the structural integrity and
shape of the cell.9-11 As non-competitive inhibitors of b-1,3-glucan synthase, echinocandins
reduce b-1,3-glucan levels leading to loss of fungal cell wall integrity and osmotic disruption of
the fungal cells.12-16 Echinocandins are primarily used to treat Aspergillus spp. and Candida spp.
infections. They are fungistatic against Aspergillus spp. and only moderately fungicidal against
Candida spp.7, 17-20 Infections are often refractory to treatment with echinocandins due to their
mechanism of action resulting in their use against a limited spectrum of fungi.21, 22
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Induction of apoptosis in fungal cells is an area that holds an immense opportunity for the
development of new antifungals, because factors that are involved in the induction of apoptosis
in yeast are different from those found in mammalian cells.23, 24 These differences afford an
opportunity to selectively target fungal cells, while minimizing the toxicological impact the
antifungal has on a patient. Cellular changes typical of mammalian cell apoptosis, such as
accumulation of reactive oxygen species (ROS), fragmentation and degradation of DNA, and
externalization of phosphatidylserine, occur in fungal cells.25 Reports have shown that
amphotericin B, a polyene antifungal drug, is capable of inducing apoptosis in fungal cells.26-28
This apoptotic response appears to occur within a narrow concentration of amphotericin B,27
while a large portion of the fungal cells die from an expected necrotic mechanism attributed to its
binding to ergosterol. Papiliocin, an antifungal first identified from a swallowtail butterfly, is
also reported to induce apoptosis in fungal cells.29 Papiliocin is believed to function in the same
manner as other cationic amphipathic peptides, causing membrane disruption and leakage of
cytoplasmic constituents. The peptide also has antibacterial activities associated with its broadspectrum membrane disruptive function. Presumably, amphotericin B also contributes to a
nonspecific disruption of membrane function, which triggers an apoptotic mechanism of cell
death in a subset of cells.30
Occidiofungin is a cyclic glyco-lipopeptide and its complete chemical composition has
been determined.31, 32 Its base molecular weight is 1200 Da (Figure 4). Occidiofungin has been
demonstrated to have a broad spectrum of antifungal activity.32, 33 Minimum inhibitory
concentrations (MICs) of occidiofungin against Candida species are between 0.5 and 2.0 µg/mL,
which is similar in activity to echinocandins and amphotericin B.33 Pharmacodynamic
experiments revealed that occidiofungin's fungicidal activity against Candida albicans is more
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rapid than the fungicidal activity reported for the echinocandin caspofungin. Occidiofungin
exhibited potent antifungal activity when Candida albicans was exposed to the antifungal for as
little as one hour, suggesting that occidiofungin has a strong interaction with a cellular target.33 A
mouse toxicity study showed that doses higher than those commonly used to treat fungal
infections did not result in mortality.34 A dose as high as 20 mg/kg resulted in no negative gross
or microscopic findings in the liver or kidneys. Hematology and serum biochemistry tests also
revealed that occidiofungin does not significantly alter organ function.
Considering that the mechanism action of occidiofungin is unknown, the aim of this
study was to determine the cause of fungal death following exposure to occidiofungin. We found
that exposure to sublethal doses of occidiofungin leads to morphological anomalies and that
exposure to lethal concentrations results in an increase in ROS, cell shrinkage, and DNA
fragmentation. Overall, our study supports an apoptotic mechanism of cell death for yeast
exposed to occidiofungin, which might be triggered by membrane perturbation.
Results
Membrane and cell wall stability
Candida albicans ATCC 66027 was used to determine whether occidiofungin activated
cell wall stress following a 10-minute and 20-minute exposure to occidiofungin (Figure 5). The
MIC value of occidiofungin in these assays was 4 µg/mL. Phosphorylation of Mkc1p indicates
the presence of oxidative stress, changes in osmotic pressure, or cell wall damage. For C.
albicans, an increase in the phosphorylation status of this MAP kinase was observable at a dose
of 250 ng/mL, which is one sixteenth less than the inhibitory concentration. A dose-dependent
increase in Mkc1p phosphorylation at 10 minutes was also seen for C. glabrata (Appendix
Figure 11). Mkc1p phosphorylation occurred at 125 ng/mL occidiofungin, one half the
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concentration seen for C. albicans. Both C. albicans and C. glabrata had a maximum increase in
Mkc1p phosphorylation at 1 µg/mL. The decreased levels of Mkc1p phosphorylation at 2 µg/mL
and the absence of Mkc1p phosphorylation at 4 µg/mL is likely due to the increased cell death
occurring at these concentrations. Similarly, an increase in the level of phospho-Cek1p indicates
that occidiofungin induces cell wall stress at subinhibitory concentrations. At the higher
concentrations of occidiofungin, phosphorylation of Hog1p, a MAP kinase in the osmotic stress
response pathway, was also detected. Although Hog1p phosphorylation was induced by
occidiofungin, the extent of activation was significantly lower than that seen for conditions
known to induce the osmotic stress response pathway (e.g. 1M NaCl).
To further analyze the impact that occidiofungin may have on cell wall integrity, MICs
were determined in media supplemented with 0.8M sorbitol. Sorbitol functions as an osmotic
stabilizer and would decrease the activity of occidiofungin if the antifungal targets cells by
disrupting membrane stability.35 MICs for C. albicans (ATCC 66027) in the presence and
absence of sorbitol in RPMI 1640 media at 24 hours were determined to be 0.5 µg/mL (Table 3).
This observation suggests that osmotic disruption, which would be predicted for a cell wall
biosynthesis inhibitor or a membrane disruptive compound, is not likely involved in the cidal
activity of occidiofungin.
Echinocandins inhibit b-1,3-glucan synthase, a multi-enzyme complex composed of
catalytic subunits Fks1p/Fks2p. Mutations in FKS1 exhibit decreased sensitivity to
echinocandins.12, 13 To determine whether occidiofungin’s mode of action is similar to that of
echinocandins, we compared the sensitivity of a Saccharomyces cerevisiae Δfks1 mutant to the
wild type strain. MIC values were similar (Table 4), suggesting that the mechanism of action of
occidiofungin differs from that of echinocandins.
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Lipoformulation of ergosterol has been used in media as a competitive inhibitor of
amphotericin B.36 We made 1,2-dioleoylphosphatidylcholine (DOPC) vesicles containing 20%
ergosterol and added them to microtiter wells yielding a final concentration of ~80 µg/mL of
ergosterol. As controls we also used DOPC vesicles with no ergosterol and vesicle free media. In
these experiments we observed a 16-fold decrease in activity of amphotericin B against C.
glabrata in the presence of DOPC vesicles containing 20% ergosterol and a 2-fold decrease in
activity in the presence of DOPC vesicles with no ergosterol (Table 3). There was no change in
the sensitivity of C. glabrata treated with occidiofungin in the presence of DOPC vesicles
containing 20% ergosterol or DOPC vesicles with no ergosterol as compared to the vesicle free
control. These data suggest that binding of ergosterol is not an important component to the
activity of occidiofungin.
Morphological changes following subinhibitory dosing of occidiofungin
Cell density of C. albicans cells exposed to a sublethal concentration of occidiofungin
(0.25 µg/mL) was notably lower than that of untreated cells. To determine whether occidiofungin
inhibited cell cycle progression, bud morphology of occidiofungin treated and untreated cell
populations was scored. In budding yeast there is a correlation between cell growth and division
such that cell cycle progression can be determined visually by simply measuring the bud size.
We found that even at concentrations of occidiofungin shown to decrease cell viability; there was
no difference in cell cycle distribution between the two groups (Appendix Table 5).
SEM and TEM were used to determine whether occidiofungin caused aberrant
morphological features in Candida cells treated with a subinhibitory concentration of
occidiofungin. Comparison of untreated cells and cells grown in subinhibitory concentrations of
occidiofungin did not reveal any morphological differences by SEM (Appendix Figure 12).
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However, TEM showed a number of mild cell morphological defects in the cells grown in the
presence of subinhibitory concentrations of occidiofungin. The most dramatic defect was with
the organization of the coat (manno) proteins (Figure 6). The coat proteins appear to be reduced
(Figure 6 B, demarcated by black arrows) compared to untreated samples. TEM results also
showed the presence of intracellular inclusions (Figure 6 B, demarcated by white arrow). Cell
wall thickness was the same for treated and untreated sample supporting our Fks1 results, and
suggesting that inhibition of cell wall synthesis is not involved in the mechanism of action of
occidiofungin against yeast cells. Prior TEM microscopy studies with the non-yeast fungus
Geotrichum candidum showed loss of cell wall thickness and the accumulation of intracellular
inclusions.32 The accumulation of intracellular inclusions appears to be the common factor
between these two groups of fungi. In addition, microscopy studies using concanavalin A-FITC
fluorescence against yeast cells showed no major disruption in b-1,3-glucan distribution
(Appendix Figure 13). However, microscopy studies using calcofluor white, which binds to
chitin, did reveal some other interesting morphological differences. Calcofluor staining of C.
glabrata showed an enhanced distribution of chitin in daughter cells following exposure to a
subinhibitory concentration of occidiofungin. Enhanced chitin localization was observed
primarily at the emerging bud tips (Figure 7).
Cell death experiments
Microscopy studies were carried out on Saccharomyces cerevisiae using FUN-1 dye as a
cell viability indicator. The MIC for S. cerevisiae in these experiments was determined to be 1
µg/mL. FUN-1 is a membrane permeable dye with red and green emission properties. The dye
accumulates within the cytosol of cells (live or dead) with an intact plasma membrane to
generate a green fluorescence. In metabolically active yeast, FUN-1 is transported from the
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cytosol into a vacuole where it forms cylindrical intravacuolar structures (CIVS) that fluoresce
red.37 The viability assay indicated that the untreated cells possessed well defined vacuoles and
the presence of CIVS. However, cells exposed to 2 µg/ml of occidiofungin for 30 minutes did
not possess these cylindrical structures and appeared to have lost volume (Appendix Figure 14).
This reduction in cell size is not typical of a cell wall active antifungal which would be expected
to result in swelling or lysis of the cell. These results suggest that occidiofungin does not
function through a lytic pathway in S. cerevisiae and these results indicate the need for additional
studies in non-lytic pathways of cell death.
Microscopy assays were carried out to determine whether occidiofungin-induced cell
death through an apoptotic or autophagic pathway. TUNEL and ROS assays were performed to
determine whether occidiofungin induced an increase in ROS and double stranded DNA breaks.
In the TUNEL and ROS assays, C. albicans and S. cerevisiae cells were treated for 3 hours at
30°C. Both assays were performed with 5mM H2O2 as positive control and a solvent blank as a
negative control. In the TUNEL assay, an increase in fluorescence was observed for cells
exposed to H2O2 but not for cells treated with the solvent blank (Figure 8 B and Appendix Figure
15 A). For occidiofungin treated cells, fluorescence of increasing intensity was observed with
increasing concentration of occidiofungin. ROS was detected using DHR123 which is oxidized
to rhodamine 123 in the presence of ROS to generate a red fluorescent signal. This experiment
showed results similar to the TUNEL assay; fluorescence increased with increasing
concentrations of occidiofungin (Figure 8 B and Appendix Figure 15 B). To determine the
importance of ROS accumulation to occidiofungin mediated cell death, MIC measurements were
carried out anaerobically, conditions known to reduce ROS production.38 A reduction in
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sensitivity to occidiofungin was observed when wild type S. cerevisiae BY4741 and S. cerevisiae
BY4741 rho0 were grown under anaerobic conditions (Table 4).
We noticed a large population of S. cerevisiae cells, when exposed to occidiofungin at 1
µg/mL, showed the presence of “dancing bodies” in the vacuole. These are presumably
polyphosphate granules and have been shown to form prior to apoptotic cell death.39 Dancing
bodies are indicated by an arrow in the DIC image of cells processed for ROS detection
(Appendix Figure 15 B). As further evidence for activation of apoptosis, an increased binding of
Annexin-V-Fluos to externalized phosphatidylserine was detected with increasing concentrations
of occidiofungin without membrane disruption as would be observed with propidium iodide
staining (Figure 9 and Appendix Figure 16).
MIC measurements of S. cerevisiae deletion mutants in the apoptotic and autophagic
pathway were done to determine whether mutants defective in these pathways were resistant to
occidiofungin (Table 4). Thirteen mutants involved directly or indirectly with the apoptotic
pathway and seventeen autophagy mutants were evaluated. Among the apoptotic mutants, Δnde1,
which is a mutant of the gene encoding the cytosolic NADH for the mitochondrial respiratory
chain. Deletion of yca1, which is the gene responsible for synthesis of a cysteine protease similar
to caspase, was two-fold more resistant compared to wild type. Sensitivity of S. cerevisiae
expressing plasmid-borne human Bcl2 was tested and there was no difference in the MICs for
the plasmid-borne human Bcl2 and empty vector, thus, Bcl2 did not have a protective role in
preventing cell death. This inability to rescue occidiofungin mediated cell death was not due to
lack of Bcl2 protein expression (Appendix Figure 17). All of the autophagy mutants tested
(Δizh2, Δizh3, Δstm1, Δmre11, Δapg12, Δapg5, Δaut7, Δapg7, Δapg10, Δapg3, Δvtc1, Δvtc2,
Δvtc3, Δvtc4, Δmms22, Δatg14, and Δvps30) had the same sensitivity profile as the wild type
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strain suggesting that autophagic cell death was not a central mechanism of occidiofungin action.
Cell viability was tested for all the mutants by determining the colony forming units following a
48-hour incubation at the minimum inhibitory concentration. Deletion mutants (nde1, yca1, rny1,
rpd3, nma1, vtc2, vtc3, csg2, apg7, nuc1, hos3, and aif1) that showed at least a ten-fold higher or
lower viability than wild type after a 48-hour exposure to occidiofungin were further analyzed by
a drop assay (Figure 10). Deletion mutants nde1 and yca1, were used as a control for an increase
or decrease in sensitivity in this assay, respectively. Deletion mutants (rpd3, nma1, apg7, nuc1,
hos3, and aif1) that showed a difference in viability from wild-type, showed no difference in
sensitivity in the drop assay. Deletion mutants (rny1, csg2, vtc2, vtc3) demonstrated resistance to
occidiofungin. Gene rny1 codes for a vacuolar RNase that promotes apoptosis under oxidative
stress conditions.40, 41 Gene csg2 codes for calcium regulatory protein that is involved in
sphingolipid metabolism.42 Genes vtc2 and vtc3 code for vacuolar transport chaperone proteins
that are involved in polyphosphate accumulation and autophagic and non-autophagic vacuolar
fusion.43, 44
Discussion
The experimental findings from this study show that: 1) the mechanism of action for
occidiofungin differs from current antifungal agents used in the clinic, 2) there are morphological
changes in yeast cells exposed to sublethal concentrations of occidiofungin, 3) microscopy
studies demonstrate that occidiofungin is rapidly fungicidal against yeast, and 4) there is a
dramatic increase in ROS, double stranded DNA breakage, and externalization of
phosphatidylserine, all documented indicators of apoptosis.
The yeast cell wall is composed of chitin, b-1,3-glucan, b-1,6-glucan, and
mannoproteins, the organization of which is critical for cell survival under altering
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environmental conditions. Disruption of cell wall composition is sensed by an intracellular
signaling pathway mediated by a cascade of MAP kinases. Activation of this pathway leads to
the upregulation of genes whose protein products are involved in cell wall synthesis including
Chs3p, the catalytic subunit of chitin synthase III (CSIII). Phosphorylation of both Mkc1p and
Cek1p within a short period of time after occidiofungin addition is indicative of cell wall
damage.45-47 Further evidence for the activation of the cell wall integrity pathway comes from the
microscopy studies of chitin staining using calcofluor white. Calcofluor staining of C. glabrata
showed an enhanced distribution of chitin in daughter cells following exposure to a subinhibitory
concentration of occidiofungin (Figure 7). Localization of chitin deposits is strictly cell cycle
dependent. Fks1p localizes at the site of active cell wall growth and no cell wall material is
deposited in the mother cell during bud growth.48 Chs3p is primarily responsible for the
production of the chitin found in the septal ring and the majority of the cell wall. The increased
chitin deposition at the site of bud growth should be the result in an upregulation of chitin
synthase activity and this increase is known to occur in response to mutations resulting in cell
wall weakening mutations or hypo-osmotic stress.49, 50 Activation of the cell wall integrity
pathway is not unique to occidiofungin as the echinocandin, caspofungin, has also been shown to
induce both CHS expression and Mkc1p phosphorylation.51, 52
These results suggest that occidiofungin does perturb the membrane integrity of yeast,
however activity assays using the osmotic stabilizer sorbitol or the Fks1 mutant resulted in no
change in sensitivity compared to controls. Presumably, activation of the cell wall stress pathway
compensates for the effect of occidiofungin at the concentrations resulting in cell death in our
study. Upregulation of Hog1p, which is an osmotic disruption indicator, was significantly lower
than that seen for conditions known to induce the osmotic stress response pathway (e.g. 1M

66

NaCl). This may be attributed to a rapidly cidal function induced by apoptosis compared to
osmotic stress induced by exposure. Activation of both the Mkc1p and Hog1p MAPK pathways
have been detected in cells treated with the cell wall disruption agent zymolyase and the
oxidative stress inducer hydrogen peroxide suggesting that a level of coordinated regulation
exists between these two signaling pathways.53, 54
There were no differences in activity of occidiofungin in the ergosterol competition assay
or the Fks1 deletion mutant, which are known to confer resistance to polyenes (amphotericin B)
and echinocandins (caspofungin), respectively. Based on the results of the microscopy assays
and the MIC values of the selected mutants, it can be concluded that occidiofungin triggers an
apoptotic pathway in the fungal cell. The apoptotic mechanism reported for amphotericin B
resulted in an accumulation of cells at the G2/M phase of the cell cycle.27 However, the apoptotic
mechanism for occidiofungin resulted in no differences in cell cycle distribution, supporting
distinct differences in the apoptotic mechanism of action for occidiofungin compared to
amphotericin B. The antifungal protein osmotin also induces an apoptotic mechanism of cell
death in yeast and does not arrest cell cycle progression.55 Studies have shown that both
apoptotic and autophagic pathways can be induced simultaneously,56, 57 supporting a common
upstream signal in their respective pathways. VPS30 is essential for the transport of cytoplasmic
material, such as large proteins and organelle material, to the lysosome under starvation
conditions. Autophagy is known to be absent in null vsp30 mutants.58 Since there was no
decrease in sensitivity to occidiofungin in the S. cerevisiae Δvsp30 mutant, the non-lytic
autophagy pathway is not likely a major component in the killing mechanism of occidiofungin.
The fact that most mutants deleted for components of the autophagic pathway, except for vtc2
and vtc3, did not confer any increase or decrease in sensitivity to occidiofungin suggests that
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autophagy is not a key pathway activated by occidiofungin and that the apoptotic pathway
triggered by occidiofungin is distinctly separate from the autophagy pathway. It is likely that the
non-autophagic vacuolar fusion activity of vtc2 and vtc3 is involved in the observed resistance of
these mutants in the drop assay.
We propose that induction of apoptosis is likely the causative mechanism of cell death for
cells exposed to occidiofungin. Deletion of the caspase like enzyme, Yca1p, resulted in an
increase in resistance to occidiofungin, while there was a decrease in resistance with the deletion
of NADH dehydrogenase (Nde1). Yca1p caspase like activity is known to contribute to the
degradation of proteins under oxidative conditions and this activity contributes to apoptotic cell
death.59 Nde1p is known to provide cytosolic NADH to the mitochondrial respiratory chain and
the decrease in respiratory chain activity should contribute to a reduction in the production of
ROS that should contribute to resistance against occidiofungin. The MIC activity results for
these mutants support an apoptotic mechanism of cell death. Confocal microscopy studies clearly
reveal an increase in ROS and double stranded DNA breakage following a short exposure to
occidiofungin. Together, the studies presented in the manuscript suggest that occidiofungin
mediated cell death is primarily through apoptosis.
Studies aimed at understanding the apoptotic mechanism of cell death induced by
occidiofungin are warranted. The specific target of occidiofungin is still unknown and the
identification of the molecular target in yeast may provide an avenue for the development of
antifungal agents that have reduced toxicity in mammalian cells. Occidiofungin is resistant to
gastric proteases33 and may provide an alternative to azoles, which are the only orally available
class of antifungals. An understanding of occidiofungin’s function may provide novel
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opportunities towards the development of other new antifungal compounds for the treatment of
serious fungal disease.
Experimental section
Antifungal preparation
Isolation of the antifungal compound was accomplished as previously reported.60 In brief,
Burkholderia contaminans MS14 was incubated at 28oC for 7 days without shaking. The cell
free culture extract was precipitated using ammonium sulfate (50% w/v) on ice for 2 hours. The
pellet was resuspended in 1 mL of 35% acetonitrile (ACN):water (v/v) and placed in a 1.5 mL
microcentrifuge tube. RP-HPLC was done using a 4.6 × 250 mm C18 column (Grace-Vydac,
catalog 201TP54) on a Bio-Rad BioLogic F10 Duo Flow with Quad Tec UV-Vis Detector
system with a 30 minute gradient from 10 to 90% (ACN):water (v/v). Purified occidiofungin
elutes as a doublet peak around 45% (Appendix Figure 18).
Strains, media, and plasmids
C. albicans (ATCC 66027), C. glabrata (ATCC 66032), and S. cerevisiae (BY4741)
strains were used for all experiments described. All strains were maintained on Sabouraud
dextrose (SD), yeast peptone dextrose (YPD), or synthetic selective media (-leucine) with 2%
agar added for solid media. Candida spp. were also grown in RPMI-1640 with MOPS media
where indicated. To express the human Bcl2 gene in yeast, primers were designed to amplify the
Bcl2 coding sequence by PCR using pDNR-Dual-Bcl2 plasmid as the template (PMID
16512675).61 Standard molecular techniques were used to clone the resulting DNA fragment into
the LEU2-marked pRS415 plasmid downstream of the constitutive GAPDH promoter and in
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frame with a C-terminal HA3 (three haemagglutinin) epitope tag. All constructs were confirmed
by sequencing before use.
In vitro susceptibility testing
Minimal Inhibitory Concentrations (MICs) were determined using Clinical Laboratory
Standards Institute (CLSI) method M27-A3. Prior to susceptibility testing, yeasts were
subcultured and grown for 24 hours on fresh SD, YPD, or -leucine media. MIC endpoints were
reported based on consistency in sensitivity differences from wild-type S. cerevisiae BY4741
after 24 and 48 hours of incubation. Susceptibility testing was done in experimental triplicate of
technical duplicates. Dimethyl sulfoxide (DMSO) was used as a negative control. The strains on
which the MICs were performed included haploid mutants of wild type Saccharomyces
cerevisiae BY4741 obtained from the yeast deletion collection in which the entire open reading
frame of each gene was deleted (Thermo Scientific).
Colony forming units (CFUs) were determined in duplicate by plating 100 µL from the
MIC wells following the 48-hour exposure to occidiofungin onto a YPD plate. In addition, 100
µL from two-fold serial dilutions of the cell suspension in YPD broth were plated to aid in
determining the CFUs. Deletion mutants (apg7, aif1, csg2, hos3, nde1, nma1, nuc1, rny1, rpd3,
vtc2, vtc3, and yca1) that had more than a 10-fold increase or decrease in CFUs were tested by a
yeast drop assay. For the drop assay, yeasts were taken from a 24-hour YPD plate and
resuspended in 5 mL of YPD to an OD530 of 0.095 (density of a 0.5 McFarland standard). The
suspension was divided into two samples of 0.8 mL each and occidiofungin was added to one
sample at 0.5 µg/mL which is equivalent to 0.5X MIC for this cell density. After 4hrs at 30˚C,
200 µL aliquots were placed onto a 96-well microtiter plate and the cells were five-fold serially
diluted seven times using YPD as the diluent. Then, 2 µL from each well was spotted to YPD
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plates in duplicate. Photos were taken after a 72-hour incubation at 30˚C. Drop assays were
carried out in duplicate.
In the sorbitol protection assay, MIC values were determined using Candida glabrata
66032 using the in vitro susceptibility assay described above except that 0.8M sorbitol was
included in the suspension media. Assays were performed in duplicate and MICs were read 24
hours following incubation at 35˚C.
MIC measurements in the presence of ergosterol were performed using C. glabrata
66032. 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) was purchased from Avanti Polar
Lipids (Alabaster, AL) and ergosterol was purchased from Sigma-Aldrich (St. Louis, MO).
Vesicles were prepared using a standard sonication procedure provided by Avanti Polar Lipids in
which 20 mg of DOPC with and without 2 mg of ergosterol was dissolved in 1mL of chloroform.
The lipid-chloroform solution was placed in a 250 mL flask attached to a vacuum line at room
temperature and dried to remove the chloroform. The dry lipid film was hydrated in 1.0 mL of
RPMI 1640 media. The suspension was added to the microtiter wells yielding a final
concentration of ~80 µg/mL of ergosterol. Each microtiter well contained a series of
occidiofungin concentrations as described above for the in vitro susceptibility assay.
Amphotericin B was used as a positive control, while DOPC vesicles containing no ergosterol
were used as a negative control. The MICs were determined after 24 hours of incubation at 35˚C.
Monitoring cell-cycle progression
Samples of Candida spp. were treated with 0, 0.5, 1, and 2 µg/mL occidiofungin over a
2.5-hour period with aliquots removed at 30-minute intervals for analysis. All cells were fixed
with the addition of formaldehyde to 3.7% final and stored at 4˚C until analyzed. Cells were
viewed by phase contrast microscopy (100X objective) and multiple random images were
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captured using a Retiga EXi Black and White CCD Camera and Image Q software. A minimum
of 250 cells per time point per treatment were scored for cell cycle distribution using bud size as
a marker for position within the cell cycle.
Protein extracts and western blot analysis
C. albicans (ATCC 66027) and C. glabrata (ATCC 66032) strains were grown in YPD at
35˚C until reaching an OD600 of 0.5. The cultures were split and occidiofungin added to achieve
a 2-fold series of concentrations ranging from 4 to 0.062 µg/mL. Samples were returned to 35˚C
with shaking for 10 or 20 minutes. For each sample, an equivalent number of cells were isolated
by centrifugation, and the resulting cell pellets stored at -20˚C. Total cellular protein was isolated
by alkaline lysis,62 separated by SDS polyacrylamide gel electrophoresis (PAGE), and
transferred to nitrocellulose for Western blot analysis. Activation of the cell wall integrity
pathway was determined using phospho-specific antibodies against p44/42 MAP kinase (Cell
Signaling Technology) shown to cross react with the doubly phosphorylated form of Mkc1p
from Candida spp.45, 46 Weak cross recognition of the phosphorylated form of Cek1p was also
detected under some experimental conditions. Total Mkc1p was detected using anti-p44/42
antibodies (Cell Signaling Technology). A monoclonal antibody to 3-phosphoglycerate kinase
(Pgk1p) was used as a loading control (Molecular Probes). Activation of Hog1p was achieved by
growing cells in the presence of 1M NaCl for the time periods indicated and monitored using
phospho-specific antibodies against p38 MAP kinase (Cell Signaling Technology).
Autoradiographs were scanned and images analyzed using NIH Image J software. The ratio of
phosphorylated Mkc1p to total Mkc1p was calculated using the intensity of each protein band
taken from the same autoradiograph with the value of untreated or DMSO treated samples
normalized to one.
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For S. cerevisiae expressing plasmid-borne human Bcl2, cells were grown in -leucine
synthetic media at 30˚C until an OD600 of 0.5. An equivalent number of cells were isolated by
centrifugation, and the resulting cell pellets stored at -20˚C. Total cellular protein was isolated by
alkaline lysis,62 separated by SDS PAGE, and transferred to nitrocellulose for western blot
analysis. HA3 tagged Bcl2 protein was detected using anti-HA antibodies (Covance); an anti-3phosphoglycerate kinase (Pgk1p) antibody was used as a loading control (Molecular Probes).
Electron microscopy
For transmission electron microscopy (TEM), samples were fixed in 2.5% glutaraldehyde
pH 7.2 for 2 hours at 4˚C. Specimens were rinsed in 0.1 M phosphate buffer, pH 7.2, post-fixed
in 2% OsO4 in 0.1 M phosphate buffer for 2 hours then rinsed in distilled water and dehydrated
in a graded ethanol series. Specimens were infiltrated and embedded in Spurr’s resin and
polymerized at 70˚C for 15 hours. Thin sections (60-100 nm) were collected and mounted on 50
mesh grids. Samples were stained with uranyl acetate and lead citrate and were examined and
photographed with a JEOL 100 CX II TEM (JEOL USA, Peabody, Massachusetts) at 80 kV.
For scanning electron microscopy (SEM), C. albicans was grown in RPMI to an OD600
of 1.0 at which time occidiofungin was added to 2 µg/mL final. After 30-minute exposure, cells
were isolated by centrifugation and fixed in 2.5% glutaraldehyde in 0.1M sodium cacodylate pH
7.2. Samples were rinsed and post-fixed in osmium tetraoxide in 0.1M sodium cacodylate pH
7.2. Samples were rinsed, dehydrated through a graded ethanol series and then critical point
dried with a Polaron critical point dryer (Quorum Technologies, Newhaven, UK). Dried samples
were mounted on aluminum stubs using carbon tape, coated with gold/palladium using a Polaron
E5100 sputter coater, and viewed on a JEOL JSM-6500 FE Scanning Electron Microscope
(JEOL USA, Peabody, MA)
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Fluorescent microscopy
C. glabrata 66032 cells were grown at a sub-inhibitory concentration of occidiofungin
(0.25 µg/mL) for 24 hours at 35˚C using the CLSI method described above. Cells were fixed
with the addition of 3.7% formaldehyde to the media and stored at 4˚C until staining with
Calcofluor White (Sigma; 18909) as described by the manufacturer. To visualize mannoproteins,
cells were fixed for 30 minutes in 3.7% formaldehyde, washed in PBS, incubated with
0.1mg/ml Concanavalin A-FITC (Sigma; C7642) for 10 minutes at room temperature, and
washed again with PBS before visualization. Stained cells were visualized using a 100X
objective on a Nikon 50i fluorescent microscope. Random images were captured using a Retiga
EXi Black and White CCD Camera and Image Q software.
Cell culture for fluorescent microscopy studies was prepared as follows. S. cerevisiae
BY4741 and C. albicans (ATCC 66027) were grown overnight in YPD at 30˚C. The cell
suspension was then diluted to 0.1 OD600 with YPD and incubated at 30˚C until the culture
reached an OD600 between 0.6 to 0.8. The minimum inhibitory concentration of occidiofungin
against S. cerevisiae and C. albicans with this cell density in YPD medium is 2 µg/mL. Images
were acquired using Olympus confocal microscope with a 40x/0.90 dry objective.
Viability assay using FUN-1 dye (Invitrogen) was carried out by adding 15µM of dye to
the untreated cells and cells treated with 2µg/mL of occidiofungin and incubating at 30˚C for 30
minutes. The cells were mounted on a glass slide and observed using an Olympus confocal
microscope. The excitation wavelength of FUN-1 is 480 nm and the emission wavelengths are
510-560 nm (green) and 560-610 nm (red). Negative control in this assay was 1.6% DMSO.
ROS detection was performed using dihydrorhodamine 123 (DHR123) (Invitrogen)
which has an excitation and emission maxima of 505 nm and 534 nm, respectively.63, 64 The dye
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(25µg/mL) was added to cells treated with 1, 2 and 4 µg/mL of occidiofungin for 3 hours.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was carried out
using the APO-BrdU TUNEL assay kit (Invitrogen). The assay was performed on cells treated
with 1, 4, and 8 µg/ml of occidiofungin for 3 hours. Protoplasts of the treated cells were obtained
by treatment of cells with 24 µg/ml of zymolyase in 1.2 M sorbitol. Staining was then carried out
according to the protocol outlined by APO-BrdU TUNEL assay kit (Invitrogen).63, 64 The dye
used in the TUNEL assay is Alexa Fluor 488 which has an excitation and emission maxima of
495 nm and 519 nm, respectively. Negative and positive controls included 1.6% DMSO and 5
mM H2O2, respectively. FITC-labeled annexin-V staining was done using Annexin-V-FLUOS
kit (Roche Applied Science).63, 64 Cells were treated with 1 and 4 µg/mL of occidiofungin for 3
hours and washed with PBS. The cell pellet was incubated in 100 µL of Annexin-V-FLUOS
labeling solution for 10-15 minutes at room temperatures, as specified by the manufacturer. The
cells were mounted on a slide and observed. Excitation and emission maxima for fluorescein are
488nm and 518nm respectively and for propidium iodide are 488nm and 617nm respectively.
Associated content
Supporting information
See Appendix. Western and microscopy data from cells treated with occidiofungin. This
material is available free of charge via the Internet at http://pubs.acs.org.
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Figures and tables
Table 3

Bioactivity of occidiofungin

Isolate

Experiment

MIC/MLC*
(µg/mL)

Bioactivity
Compared
to Control

Occidiofungin
C. glabrata 66032
C. glabrata 66032
C. glabrata 66032
C. glabrata 66032

CLSI
0.8 M Sorbitol
DOPC Vesicles
DOPC Vesicles:Ergosterol

0.5/N.D.
0.5/N.D.
0.5/N.D.
N.D./0.5

No Change
No Change
No Change

C. glabrata 66032
C. glabrata 66032

CLSI
DOPC Vesicles

0.5/N.D.
1.0/N.D.

C. glabrata 66032

DOPC Vesicles:Ergosterol

N.D./ > 8.0

2-Fold
Decrease
>16-Fold
Decrease

Amphotericin B

* Only the MLC is reported, given the turbidity of the Ergosterol DOPC suspension.
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Table 4

Occidiofungin MICs
Isolate
S. cerevisiae BY4741
S. cerevisiae BY4741 Rho
S. cerevisiae BY4741
S. cerevisiae BY4741 Rho
Membrane and
Cell Wall Mutants
S. cerevisiae Δsur1
S. cerevisiae Δipt1
S. cerevisiae Δcsg2
S. cerevisiae Δfks1p
Apoptotic Mutants
S. cerevisiae Δyca1
S. cerevisiae Δste20
S. cerevisiae Δaif1
S. cerevisiae Δhos3
S. cerevisiae Δuth1
S. cerevisiae Δnma1
S. cerevisiae Δhda1
S. cerevisiae Δnde1
S. cerevisiae Δrny1
S. cerevisiae Δrpd3
S. cerevisiae Δsir2
Autophagy Mutants
S. cerevisiae Δizh2
S. cerevisiae Δizh3
S. cerevisiae Δstm1
S. cerevisiae Δmre11
S. cerevisiae Δapg12
S. cerevisiae Δapg5
S. cerevisiae Δaut7
S. cerevisiae Δapg7
S. cerevisiae Δapg10
S. cerevisiae Δapg3
S. cerevisiae Δvtc1
S. cerevisiae Δvtc2
S. cerevisiae Δvtc3
S. cerevisiae Δvtc4
S. cerevisiae Δmms22
S. cerevisiaeΔatg14
S. cerevisiaeΔvps30

0

0

Bioactivity of occidiofungin.
*MIC recorded at 48 hours
¥

Cells were grown anaerobically
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MIC (µg/ml)
0.1250
0.1250*
0.2500
0.2500*
¥

¥

0.0625
0.0625
0.1250
0.1250
0.2500
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250
0.0625*
0.0625
0.0625
0.0625
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250
0.1250

Structure of occidiofungin
R1 represent the locations where a hydroxyl may be added to form BHN1. R2 represent the
locations where a chlorine is added to form chloro-BHY4.
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Western blot detection of MAPK activation
Candida albicans cells were treated with increasing concentrations of occidiofungin (0-4 µg/mL)
for 10 or 20 minutes. Cell extracts were analyzed by immunoblotting with antibodies against
phospho-Mkc1p, total Mkc1p, and phospho-Hog1p. Detection of phosphoglycerate kinase
(Pgk1p) was used to verify equal protein loading. Cells grown in the presence of 1M NaCl were
used as a positive control for Hog1p activation. The relative ratios of phosphorylated Mkc1p to
total Mkc1p are indicated for each set of immunoblots with the ratio of DMSO treated cells
normalized to one.
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TEM micrographs.
(A) Candida albicans cells treated with the solvent blank, DMSO. (B) Candida albicans cells
grown in a sublethal concentration of occidiofungin. The arrows revealed a loss of coat proteins
on the surface of the cell wall as well as vesicle-like inclusions inside the cell. Side panels show
an expanded region of cells having the morphological defect. Images were acquired at I2AT,
Mississippi State University.
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Chitin staining in Candida glabrata
Chitin staining was visualized with calcofluor white staining in live cells by fluorescence
microscopy using a 100X objective and a DAPI filter set. (A) Chitin localization in cells treated
with a sublethal concentration of occidiofungin. (B) Chitin localization in untreated cells. A
montage of cells is shown for each.
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Fluorescent microscopy studies on Candida albicans
(A) TUNEL Assay. Rows “1” and “2” are DIC and fluorescence images, respectively. Column
“a” shows cells treated with the solvent blank, “b” shows cells treated with 5mM H2O2 and “c-e”
correspond to cells treated with 1 µg/mL, 4 µg/mL and 8 µg/mL of occidiofungin, respectively.
(B) ROS detection assay. Rows “1” and “2” are DIC and fluorescence images, respectively.
Column “a” corresponds to treatment with solvent blank, “b” corresponds to cells treated with
5mM H2O2, and “c-e” show cells treated with 1µg/mL, 2 µg/mL and 4 µg/mL of occidiofungin,
respectively. (C) Phosphatidylserine detection assay. Rows “1” and “2” are DIC and
fluorescence images, respectively. Column “a” corresponds to treatment with solvent blank, “b”
corresponds to treatment with 5mM H2O2, and “c-e” show cells treated with 1 µg/mL, 4 µg/mL
and 8 µg/mL of occidiofungin, respectively.
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Phosphatidylserine detection assay on Candida albicans
Rows A–D are negative control (treatment with DMSO with no occidiofungin), positive control
(5 mM H2O2), cells treated with 1 µg/mL, and 4 µg/mL of occidiofungin, respectively. Columns
“a-d” correspond to DIC image, annexin fluorescence image, propidium iodide fluorescence
image, and overlay of annexin and propidium iodide fluorescence images, respectively.
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Drop assay
Growth sensitivity of S. cerevisiae deletion mutants exposed to 0.5 µg/mL occidiofungin for 4 h
was analyzed by spotting 5-fold serially diluted cells to a YPD plate. The growth profile for
untreated (−) or occidiofungin treated (+) cells are shown after 72 h at 30°C. An untreated and
treated wild type strain was included on all plates to control for experimental variations.
r
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SUBSEQUENT WORK ON OCCIDIOFUNGIN, CONCLUSIONS, AND FUTURE
DIRECTIONS

The work described in this dissertation has formed the foundation for many subsequent
studies. This chapter will present the current knowledge of occidiofungin, and where appropriate,
present a link to the findings detailed in chapters 2 and 3.
Occidiofungin has been shown to be bioactively stable following exposure to various
temperature and pH conditions, resistant to gastric protease degradation, and retains its
bioactivity profile in the presence of serum.1 These findings suggest that the compound is likely
to be stable and retain activity if introduced into an in vivo model orally. To this end, these
results were extended to investigate the toxicological properties of occidiofungin in an in vivo
murine model when administered by intraperitoneal, subcutaneous, and intravenous routes.
Studies showed the animals to have only mild behavioral changes and a dose-dependent loss of
total body weight.2, 3 No other toxicities were identified. Occidiofungin has also been evaluated
against both normal and cancerous cell lines including ovarian cancer (OVAR8), astrocytoma
brain cancer (SW1088), and B-cell non-hodgkin lymphoma cancer (TOLEDO CRL-2631). All
three cancerous cell lines were found to be more susceptible to occidiofungin at a range of 61-70
nM.3 This activity is seven-eight fold higher than the noncancerous cell lines tested and ten- to
twenty-fold higher than the Candida species tested, suggesting that in addition to its antifungal
activities, occidifungin may have promise as an anti-cancer drug. The antifungal compound has
92

also recently been shown to be effective at clearing a murine model vaginal infection of Candida
spp., establishing potential clinical relevance.4 Future studies will need to be expanded to include
the therapeutic possibilities of occidiofungin against a murine model of systemic infection, and
ultimately clearance of vaginal infections in human clinical trials.
The compound and the complexity of occidiofungin, a cyclic peptide containing novel
nonproteinogenic amino acids, an 18-carbon lipid, and a xylose, necessitate identification of the
minimal core components required for bioactivity. The identification of the 56 kb occidiofungin
operon in Burkholderia contaminans presented one approach towards identification of the
minimal core components required for bioactivity. Focusing on the ocfC gene, a 9 putative
galactosyltransferase, determined that xylose addition to occidiofungin was not required to retain
bioactivity, rather it was required to maintain a higher yield of the secreted antifungal product.5
This newfound information could be useful in future production of the drug for clinical and
agricultural use as it is now known that the xylose group is vital to maintaining higher output of
bacterially produced occidiofungin. Additional occidiofungin variants include the chemical
modification of the position five free amino group of the diaminobutyric acid with a terminal
alkyne for use in click-based chemistry.4 The addition of a fluorophore group reduced antifungal
activity by 8-fold, but allowed for studies aimed at monitoring cellular location of occidiofungin
in fungal cells. Retention of some level of antifungal activity following chemical modification
opens up possibilities at identifying the cellular target.
Initial studies aimed at identifying the biological target of occidiofungin looked at
whether exposure to the antifungal resulted in cells accumulating at a particular stage of the cell
cycle by scoring bud morphology. Analysis found that occidiofungin exposed cells did not
accumulate with any one bud morphology suggesting that the biological target of occidiofungin
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is present across the cell cycle.1 This is beneficial for an antifungal compound as cells at any cell
cycle stage will be susceptible. However, subsequent studies have shown that cells that have
entered quiescence are resistant to occidiofungin.6 This suggests cells must be actively dividing
to be susceptible to occidiofungin. This is not unique to occidiofungin as other drugs have been
known to have resistance profiles against cells in quiescence.7 This suggests cells must be
actively dividing to be susceptible to occidiofungin fungicidal activity. Taken together with the
data showing occidiofungin to be potent against various cancer cell lines, it was speculated that
occidiofungin’s biological target is essential for the viability of metabolically active cells.3
Apoptosis as a mechanism of cell death may be ideal for an antifungal drug as
programmed method of death compartmentalizes cellular components as it breaks down and is
followed by host immune cell phagocytosis which minimizes the immune response.8 Our
research identified numerous hallmarks of apoptotic cell death following occidiofungin treatment
including nuclear DNA fragmentation, elevated ROS levels, extracellular localization of
phosphatidylserine, and the presence of ‘dancing bodies’.1 These data, combined with the fact
that the resistance profile of cells in quiescence is lost once they reenter the cell cycle,6 has led to
the hypothesis that cells must be actively dividing to be susceptible to this antifungal compound.
Cells that are metabolically active constantly restructure and reorganize their actin. Interestingly,
apoptosis has been shown to be induced when actin dynamics are altered, whether stabilized or
depolymerized.9, 10 Recent research has shown that actin can trigger apoptosis when cells are
unable to respond to environmental cues such as depletion of glutathione, acetic acid, and
H2O2.11, 12 As an essential cytoskeletal element, actin is present at all stages of the cell cycle and
is involved in diverse cellular processes such as polarization of the cell, endocytosis,
contractility, trafficking of vesicles, and cytokinetic ring formation.13 Recent studies directly
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assessed the role of actin in occidiofungin bioactivity. Findings identified that occidiofungin
exposed cells had delayed uptake of FM-464, defects in nuclear positioning, and inability to form
hyphae under morphogenic switching conditions. As all of these processes require stable actin
filaments, the direct binding of occidiofungin to actin was also tested.4 Using an occidiofungin
variant modified with a functional alkyne group bound to both F-actin and G-actin from purified
skeletal rabbit actin in vitro.4
Therefore both in vivo and in vitro data suggest that occidiofungin targets actin, setting
up new questions that remain to be addressed. For example, actin is a highly conserved protein.
How can it be the target of occidiofungin in fungi without exhibiting toxicity to mammalian
cells? At the amino acid level, yeast actin (S. cerevisiae) and mammalian muscle actin are 87%
identical, however yeast are unable to survive when muscle actin is the sole source of actin
available.14 This points to significant differences in mammalian and yeast actin which could
attribute to occidiofungin not being toxic to mammalian cells. Although the occidiofungin bound
to purified rabbit skeletal muscle F-actin in vitro, this may not be the same as occidiofungin
binding to mammalian actin in vivo as the available actin in vivo of mammalian cells is not
purified.3, 4 The dependence of cellular activities on F-actin also differs between mammalian and
fungal cells. Mitochondria are highly dependent on actin filaments for fusion and fission based
events as well as their distribution of mitochondria along with vacuoles during cell division,
activities which rely more on microtubules in mammalian cells.14 According to one study, yeast
actin is faster at polymerizing, nucleotide exchange rates, releasing Pi, compared to mammalian
muscle actin.15 All these findings could potentially account for the lack of toxicity in mammalian
cells and susceptibility to occidiofungin in yeast as actin in yeast and mammalian cells function
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differently. Further testing in the way of clinical trials needs to be carried out to see whether or
not occidiofungin has any toxic impacts on human subjects.
Additional problems remain to be addressed for occidiofungin to be a viable candidate
for clinical trials. As a natural product, what can be done to increase the yield of the drug such
that sufficient amounts are available for clinical testing? It is possible that introducing yeast cells
to the media Burkholderia contaminans MS14 is grown in could potentially induce an increase in
production of occidiofungin by the bacteria as the fungicidal compound is produced as a
response to fungal pathogens. Future testing should be done to test this theory.
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Table 5

Impact of occidiofungin on cell cycle distribution
A.
G1
Occidiofungin
0.5 µg/mL
0 hr
1.5 hr
1 µg/mL
0 hr
2 hr
2 µg/mL
0 hr
2 hr

-

S
+

-

+

G2/M
- +

Other
- +

45 42 18 19 31 31 5 7
44 46 17 15 26 26 14 14
34 42 22 24 27 19 17 16
40 24 21 24 18 26 21 26
35 35 19 19 34 28 12 18
40 33 21 24 23 25 16 18

B.
Occidiofungin
0.5 µg/mL
0 hr
1.5 hr
1 µg/mL
0 hr
2 hr
2 µg/mL
0 hr
2 hr

log10 (CFUs/mL)
+
6.56
6.63
6.62
6.9
6.58
6.81

6.49
6.53
+
6.53
5.69
+
6.48
5.60

Occidiofungin was added to a logarithmically growing culture of Candida albicans to achieve
concentrations of 0.5µg/mL, 1µg/mL, and 2µg/mL final. At the indicated times, cells were
removed and processed for cell morphology (A) and cell viability by CFU determination (B).
Data are from three independent experiments with the average percent of cells at each stage of
the cell cycle given. Cell morphology was scored based on the following morphological criteria:
unbudded cells are in G1; small budded cells are in S; medium and large budded cells are in
G2/M. Cells placed in the ‘other’ category had multiple buds or a filamentous morphology.

101

Western blot detection of MAPK activation in Candida glabrata
Cells were treated with increasing concentrations of occidiofungin (0-4 µg/mL) for 20 minutes.
Cell extracts were analyzed by immunoblotting with antibodies against phospho-Mkc1p, total
Mkc1p, and phospho-Hog1p. Detection of phosphoglycerate kinase (Pgk1p) was used to verify
equal protein loading. The relative ratios of phosphorylated Mkc1p to total Mkc1p are indicated
with the ratio obtained for untreated cells set to one.
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Scanning electron microscopy (SEM) images of Candida albicans
Untreated (a) and occidiofungin treated (b) cells. C. albicans cells were propagated at 35˚C in
RPMI until reaching an OD600 of 1.0. Occidiofungin (2 µg/mL), or an equivalent volume of
DMSO, was added and cells returned to 35˚C for 30 minutes. Cells were isolated by
centrifugation and processed for SEM as described in Materials and Methods. 4000X
magnification is shown. Images were acquired at I2AT, Mississippi State University.
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Cell wall mannoprotein distribution in Candida glabrata
Cell wall mannoprotein distribution in Candida glabrata treated with occidiofungin remains
unchanged. Candida glabrata cells were grown for 24hr in the absence (A) or presence (B) of a
sublethal concentration of occidiofungin. 1,3-b-glucan was visualized with concanavalinA-FITC
staining by fluorescence microscopy. A montage of cells is shown for each treatment.

104

FUN-1 assay
DIC and fluorescence images of yeast cells stained with FUN-1. Panels “a-d” are untreated yeast
cells. CIVS stained red with FUN-1(shown by arrows). Panels “e-h” are occidiofungin treated
cells (2µg/ml). CIVS not present in cells. Panels “a” and “e" are DIC images. Panels “b” and “f”
are the green emission, while “c” and “g” are the red emission channels. Panels “d” and “h” are
overlays of “a-c” and “e-g”, respectively.
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Fluorescent microscopy studies on S. cerevisiae
(A) TUNEL assay. Rows “1” and “2” are DIC and fluorescence images, respectively. Column
“a” shows cells treated with the solvent blank, “b” shows cells treated with 5mM H2O2 and “c-e”
correspond to cells treated with 1 µg/mL, 4 µg/mL and 8 µg/mL of occidiofungin, respectively.
(B) ROS detection assay. Rows “1” and “2” are DIC and fluorescence images, respectively.
Column “a” corresponds to treatment with solvent blank, “b” corresponds to cells treated with
5mM H2O2, and “c-e” show cells treated with 1µg/mL, 2 µg/mL and 4 µg/mL of occidiofungin,
respectively.
106

Phosphatidylserine detection assay on S. cerevisiae
Rows A-D are negative control (treatment with DMSO with no occidiofungin), positive control
(5mM H2O2), cells treated with 1 µg/mL, 4 µg/mL of occidiofungin, respectively. Columns “a-d”
correspond to DIC image, annexin fluorescence image, propidium iodide fluorescence image, and
overlay of annexin and propidium iodide fluorescence images, respectively.
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Western blot analysis
Constitutive expression of HA3 tagged Bcl2 protein was observed. Anti-HA antibodies was used
to detect HA3 tagged Bcl2 protein and anti-3-phosphoglycerate kinase (Pgk1p) antibody was
used as a loading control.
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RP-HPLC chromatogram
50 µg of purified occidiofungin
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